

1 **Title Page**

2 **Title: Dysregulation in Spatiotemporal Expression of *HMX1* Coordinated by Multifaceted 3 Enhancers Drives an Auricular Disorder**

4 **Authors:** Xiaopeng Xu^{1,2,*}, Qi Chen^{3,*}, Qingpei Huang^{1,*}, Timothy C. Cox^{4,*}, Hao Zhu², Jintian Hu³,
5 Xi Han¹, Ziqiu Meng², Bingqing Wang³, Zhiying Liao¹, Wenxin Xu^{1,5}, Baichuan Xiao², Ruirui
6 Lang², Jiqiang Liu², Qiang Li⁶, Qingguo Zhang³, Stylianos E. Antonarakis^{7,8,9}, Jiao Zhang^{10,#},
7 Xiaoying Fan^{1,#}, Huisheng Liu^{1,#}, Yong-Biao Zhang^{2,11,#}

8 **Affiliations:**

9 ¹ School of Biomedical Engineering, GMU-GIBH Joint School of Life Sciences, The Fifth
10 Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou
11 National Laboratory, Bioland Laboratory, Guangzhou, 510320, China

12 ² School of Bioengineering Medicine, Beihang University, 100191, China

13 ³ Department of Ear Reconstruction, Plastic Surgery Hospital, Chinese Academy of Medical
14 Sciences, Beijing 100144, China

15 ⁴ Departments of Oral & Craniofacial Sciences, School of Dentistry, and Pediatrics, School of
16 Medicine, University of Missouri-Kansas City, Kansas City, USA

17 ⁵ Division of Life Sciences and Medicine, University of Science and Technology of China (USTC),
18 Hefei, 230000, China

19 ⁶ Department of Plastic Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000,
20 China

21 ⁷ Department of Genetic Medicine and Development, University of Geneva Medical Faculty,
22 Geneva 1211, Switzerland

23 ⁸ Medigenome, Swiss Institute of Genomic Medicine, 1207 Geneva, Switzerland

24 ⁹ iGE3 Institute of Genetics and Genomes in Geneva, Geneva, Switzerland

25 ¹⁰ Shandong collaborative innovation research institute of traditional Chinese medicine industry

26 ¹¹ Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of

27 Industry and Information Technology

28 **Correspondence:**

29 Yong-Biao Zhang, Address: 37 Xueyuan Road, Haidian District, Beijing, 100191, China, Tel: +86

30 13522471691, Email: zhangyongbiao@gmail.com

31 Huisheng Liu, Address: 9th Xingdaohuan North Road, Guangzhou International Bio Island, Haizhu

32 District, Guangzhou, Guangdong, 510320, China, Email: liu_huisheng@gzlab.ac.cn

33 Xiaoying Fan, Address: 9th Xingdaohuan North Road, Guangzhou International Bio Island, Haizhu

34 District, Guangzhou, Guangdong, 510320, China, Email: fan_xiaoying@gzlab.ac.cn

35 Jiao Zhang, Address: Minghu International Cell Medicine Industrial Park, Jingshi Road, Lixia

36 District, Jinan, 250000, China, Email: joycezhang1978@hotmail.com

37 *The authors wish it to be known that, in their opinion, the first four authors should be regarded as

38 joint first authors

39 **Abstract**

40 Enhancers, through the combinatorial action of transcription factors (TFs), dictate both the spatial
41 specificity and the levels of gene expression, and their aberrations can result in diseases. The
42 association between *HMX1* and its downstream enhancer with ear deformities has been previously
43 documented. However, the pathogenic variations and molecular mechanisms underlying the
44 bilateral constricted ear (BCE) malformations remain unclear. This study identifies a copy number
45 variation (CNV) encompassing three enhancers that induces BCE. These enhancers, collectively
46 termed the positional identity hierarchical enhancer cluster (PI-HEC), co-regulate spatiotemporal
47 expression of the *HMX1* gene in a coordinated and synergistic mode, each displaying unique
48 activity-location-structure characteristics. A thorough exploration of this regulatory locus reveals
49 that specific motif clusters within the PI-HEC variably modulate its activity and specificity, with the
50 high mobility group (HMG) box combined with Coordinator and homeodomain (HD)-TFs notably
51 influencing them respectively. Our findings based on various types of mouse models, reveal that
52 both aberrant *Hmx1* expression in the fibroblasts of the basal pinna, originating from neural crest
53 cells, and ectopic expression in the distal pinna structures contribute to the abnormal development
54 of the outer ear, including the cartilage, muscle, and epidermis tissues. This study deepens our
55 understanding of mammalian ear morphogenesis and sheds light on the complexity of gene
56 expression regulation by enhancers and specific sequence motifs.

57

58

59 **Introduction**

60 Investigating the intricate morphological changes during mammalian embryogenesis remains a
61 pivotal focus in developmental biology, a discipline that has recently seen significant progress¹.
62 The mammalian ear, a complex structure originating from cranial neural crest cells (CNCCs) and
63 all three germ layers, exemplifies the complexity of developmental biology. It showcases a unique
64 interplay of developmental processes and evolutionary adaptation^{2,3}. The outer ear, essential for
65 capturing sound waves and implicated in conductive hearing loss when dysfunctional, is less
66 explored than its middle and inner counterparts³. This part, comprising the tragus and helix, is not
67 only important for auditory function but also demonstrates considerable morphological diversity
68 throughout evolution as well as in many types of diseases⁴⁻⁷. Unraveling the molecular mechanisms
69 underlying this diversity is an ongoing field of investigation.

70 Bilateral constricted ear (BCE) often presents as an autosomal dominant trait and primarily
71 manifests as curling of the upper portion of the external ear, affecting structures such as the helix,
72 scapha, and antihelix. Comparative genetic studies across species, including sheep, cows, mice, and
73 rats, have identified a correlation between BCE-like phenotypes and a non-coding regulatory region
74 adjacent to the *Hmx1* gene that contains an evolutionarily conserved region (ECR)^{8,9}. In humans,
75 phenotypic presentations similar to those in concha-type microtia have been linked to genomic
76 duplications encompassing the ECR near *HMX1*¹⁰. Notably, in rats, a 5.7-kb deletion that includes
77 this ECR significantly diminishes *Hmx1* expression, leading to a dumbo ear phenotype, highlighting
78 a critical regulatory role¹¹. Furthermore, in human concha-type microtia, several genomic
79 duplications exist that extend beyond the ECR, suggesting a complex and multifaceted genetic
80 mechanism underlying outer ear development. The spectrum of pathogenic mutations involving the

81 ECR, including both duplications and deletions, emphasizes the complex interplay of gene
82 expression in determining ear morphology.

83 Elucidating the function of cis-regulatory elements in specific cellular and temporal settings is
84 key to unraveling the complex mechanisms of ear development and regulatory variations that
85 influence the external ear phenotype^{12,13}. Recent research underscores CNCCs as vital in
86 craniofacial development, including the outer ear¹⁴⁻¹⁶. CNCCs positional identity is determined by
87 a complex set of signaling factors that govern a distinct hierarchy of gene expression profiles. For
88 example, positional identity along the anterior-posterior axis is influenced by bivalent gene
89 expression such as *Hoxa2* in the second pharyngeal arch and *Hand2* in the mandibular arch¹⁷. Along
90 the proximo-distal axis, gene expression of *Dlx* homeobox family members, for example, governs
91 patterning within the mandibular arch. Patterning along all axes is crucial for proper craniofacial
92 morphogenesis¹⁸. This highlights the importance of precise CNCCs positional identity¹⁹. For
93 instance, ectopic *Hoxa2* expression in the pharyngeal arch 1 (PA1) results in mirror-image pinna
94 duplication⁷, while the loss of *Dlx5* and *Dlx6* in the mandibular arch results in the transformation of
95 the lower jaw into a mirror image of the upper jaw components²⁰. Single-cell RNA sequencing
96 (scRNA-seq) studies of the mandibular arch further revealed a wide range of heterogeneous cellular
97 domains (intra-arch identity), with disturbances leading to specific mandible and tooth defects²¹.
98 Yet, the exact regulatory mechanisms of spatial gene expression in the craniofacial region, including
99 *HMX1*, and within individual arches, are not fully understood. This knowledge gap limits our
100 understanding of the genetic and epigenetic dynamics in human craniofacial morphogenesis.

101 This investigation presents a comprehensive analysis of human pedigrees with BCE,
102 employing gene chips and next-generation sequencing to pinpoint a pathogenic locus, designated as

103 the BCE locus on chromosome 4. This locus encompasses an enhancer cluster, comprising three
104 synergistically acting enhancers identified in human craniofacial tissues and *in vitro*-derived human
105 CNCCs (hCNCCs). Transgenic LacZ mouse experiments revealed that the spatial specificity of the
106 *Hmx1* gene expression in pharyngeal arch 2 (PA2) during ear development is governed by a
107 hierarchical interplay among these enhancers, forming what we term the Positional Identity
108 Hierarchical Enhancer Cluster (PI-HEC). In-depth examination of the dominant enhancer in PI-
109 HEC unraveled a complex network of transcription factors (TFs) modulating enhancer specificity
110 and function. Gene-editing in mouse models elucidated the link between pinna development and
111 altered *Hmx1* expression, exposing a dysregulated molecular network affecting pinna structures
112 such as cartilage, muscle, and epidermis. Our findings significantly advance the understanding of
113 the genetics and regulatory mechanisms behind human outer ear development, providing novel
114 molecular insights into the etiology of pinna development and the presentation of BCE.

115 **Results**

116 **Copy number duplications detected in BCE**

117 We explored the genetic basis of BCE, a condition noted in seven Chinese families showing
118 autosomal dominant inheritance, using classical linkage analysis with genechip genotyping (**Fig. 1a**
119 **and 1b**). Linkage analysis on pedigrees 1, 3, and 6 yielded a significant combined parametric LOD
120 score of 7.8 (**Extended Data Fig. 1a**), with individual scores of 2.7, 1.8, and 3.3 respectively
121 (**Extended Data Fig. 1b**). This led to the mapping of the susceptible locus to a 10.2 cM region on
122 chromosome 4 (**Extended Data Fig. 1b**).

123 For fine mapping of this locus, target-capture sequencing was performed on 32 individuals
124 across the three pedigrees. This detailed analysis revealed copy number duplications co-segregating
125 in all sequenced patients from the three pedigrees (**Extended Data Fig. 1c**). The specific genomic
126 ranges of these duplications were chr4:8691119-8795306, chr4:8679801-8750713, and
127 chr4:8668379-8739905 (hg19) for each respective pedigree. Further investigations using chip-based
128 methods and whole-genome sequencing in the remaining four pedigrees confirmed that probands in
129 each of these pedigrees also carried copy number duplications in this non-coding region (**Fig. 1c**).

130 Ultimately, our findings converged on a minimum genomic region of overlap of chr4:8691119-
131 8726565 (termed the BCE locus), consistently present across all seven BCE pedigrees. Hi-C data
132 from human embryo head tissue of CS17 stage²², revealed the TAD structure around the BCE locus,
133 suggesting that *HMX1* and *CPZ* are potential target genes (**Fig. 1c**).

134 **The BCE locus, containing a cluster of enhancers, directly interacts with the *HMX1* promoter**

135 Previous studies have identified a conserved enhancer within the BCE locus that participates in the
136 regulation of *Hmx1* gene expression across different mammals^{8,11}. However, understanding of the

137 full range of cis-regulatory elements at this locus, including their context-dependent characteristics
138 and their role in controlling pinna development, remains incomplete. Given the spatiotemporal
139 specificity of cis-regulatory elements, it is imperative to study them within embryonic contexts that
140 are closely associated with pinna development. Studies in mice indicated that CNCCs are important
141 for pinna organogenesis⁷, and both murine studies¹¹ and single-cell sequencing data of human
142 embryos²³ also indicated that *HMX1* is predominantly expressed in the craniofacial mesenchyme,
143 including the PA1/2 and PA3/4 regions (**Extended Data Fig. 2a**). These data underscore the
144 necessity of concentrating our research on CNCCs and craniofacial mesenchyme to thoroughly
145 investigate cis-regulatory elements within the BCE locus and their roles in pinna development
146 (**Extended Data Fig. 2a**).

147 To delineate the cis-regulatory elements at the BCE locus, we interrogated publicly available
148 ChIP-seq data from both *in vivo* embryonic human head tissues (CS13-CS17)²⁴ and *in vitro*-derived
149 hCNCCs²⁵. This approach revealed a cluster of potential enhancers (termed EC1, EC2, and EC3)
150 within the BCE locus across these datasets: EC1 and EC2 are both active in two datasets, EC3 was
151 defined as an active enhancer *in vivo* but possesses weak histone signals *in vitro* (**Fig. 2a**). Consistent
152 with findings in the human datasets, analogous sequences in publicly available mouse CNCCs
153 (mCNCCs) data¹⁷ were also identified as an enhancer cluster, notably in PA2 (**Extended Data Fig.**
154 **2b**). Comparative analyses employing Promoter Capture Hi-C (PC-HiC) revealed that the enhancer
155 cluster region actively interacts with the *HMX1* promoter in hCNCCs, but not in human Embryonic
156 Stem Cells (hESCs) (**Fig. 2b and Supplementary Table 1**). This observation suggests that the
157 activity of the enhancer cluster is temporally regulated and cell-type specific, favoring *HMX1* and
158 excluding interaction with the adjacent gene *CPZ*. Publicly available mouse PC-HiC data²⁶ further

159 revealed that the BCE locus interacts with the *Hmx1* promoter in PA2 tissue of E10.5 and pinna
160 structures of E12.5 and E14.5 (**Extended Data Fig. 2c**). The collective evidence suggests a
161 conserved role of the enhancer cluster in modulating *HMX1* expression in CNCCs, necessitating
162 further clarification of how enhancers within this complex coordinate the spatiotemporal pattern of
163 *HMX1* expression.

164 **Different intrinsic activities of the three enhancers at the BCE locus during hCNCCs
165 differentiation**

166 To investigate the spatiotemporal modulating patterns of the individual candidate enhancers hEC1,
167 hEC2, and hEC3 within the enhancer cluster, we further conducted a detailed analysis of epigenetic
168 datasets of two developmental stages of *in vitro* derived hCNCCs^{25,27}: early (D11), representing
169 cells migrating out of the neural rosettes, and late (P4), representing post-migratory mesenchymal
170 cells (**Fig. 3a**). Active enhancer markers, P300 and H3K27ac, revealed distinct profiles: hEC1
171 displayed significant activity in late hCNCCs; hEC2 was divided into two regions, hEC2.1 and
172 hEC2.2, based on P300 signals; hEC2.1 showed strong H3K27ac activity at both stages, whereas
173 hEC2.2 exhibited weaker H3K27ac activity, indicating a less active state at both stages; hEC3,
174 despite showing strong accessibility in late hCNCCs and interaction with the *HMX1* promoter (**Fig.**
175 **2b**), lacked H3K27ac signals (**Fig. 3a**).

176 To evaluate the capacity of the candidate enhancers to drive reporter gene expression, we
177 adapted a well-established *in-vitro* differentiation system²⁸, further incorporating retinoic acid (RA)
178 at the late hCNCCs stage to induce transformation into PA (pharyngeal arch)-like hCNCCs
179 characteristic (**Fig. 3b and Extended Data Fig. 3**). *HMX1* gene expression initially rose
180 approximately 4-fold at the early hCNCCs stage, and subsequently surged to about 140-fold at the

181 late hCNCCs stage and 110-fold at the PA-like hCNCCs stage (**Fig. 3c**). In luciferase assays, none
182 of the enhancers showed activity in H9 cells, consistent with the inaccessibility of these enhancers
183 in hESCs (**Fig. 3d and Fig. 2b**). However, in PA-like hCNCCs, EC1 was a strong transcriptional
184 activator (**Fig. 3e**), while hEC2.1 and hEC2 demonstrated weaker activity than hEC1 (**Fig. 3e**).
185 Notably, hEC2.2 and hEC3 remained inactive in all tested contexts, consistent with their weak
186 H3K27ac signals (**Fig. 3d and Fig. 3e**). These findings suggest that hEC1 is a strong enhancer, hEC2
187 is a weak enhancer and hEC3 is primed for activation but it is not currently active or it may serve
188 as a structural element to facilitate the contact between the BCE locus enhancer cluster and the
189 *HMX1* promoter²⁹.

190 In a further experiment, we created knockout (KO) hESC lines with simultaneous deletions of
191 hEC1 and hEC2 (**Fig. 3f, upper panel, and Extended Data Fig. 4a**). Both wild-type and KO hESC
192 lines exhibited similar differentiation capacities into hCNCCs, and the expression levels of two
193 marker genes, *SOX9* and *TWIST1*, were similar in both lines (**Extended Data Figs. 4b and 4c**). In
194 the differentiation of hCNCCs to PA-like cells, *HMX1* expression remained similar between wild-
195 type and KO cells at the H9 state, but diverged noticeably at the early hCNCCs stage, becoming
196 more pronounced in the late and PA-like hCNCCs stages (**Fig. 3f, bottom panel**). In summary, our
197 results establish the relationship between *HMX1* expression and enhancer activities in the BCE locus
198 in different stages of hCNCCs development.

199 ***Hmx1* gene patterning along pinna development is related to epistatic interactions of the three
200 enhancers in the BCE locus**

201 We employed the whole-mount *in-situ* hybridization (WISH, E9.5) and transgenic *Hmx1*-P2A-
202 EGFP mouse reporter line (E11.5 and E14.5) to elucidate the spatiotemporal dynamics of *Hmx1*

203 expression during embryonic ear development. Specifically, we focused on three developmental
204 stages: embryonic day 9.5 (E9.5), representing early CNCCs development stage in PAs; E11.5,
205 reflecting CNCC-derived mesenchyme development stage in PAs; and E14.5, corresponding to the
206 initial stages of pinna development (**Fig. 3g and Extended Data Fig. 4j**). We observed the initiation
207 of *Hmx1* expression at E9.5 in the superior region of PA1. By E11.5, this expression expanded to
208 the eye, craniofacial mesenchyme, part of PA2, and the dorsal root ganglia (DRG). By E14.5, *Hmx1*
209 predominantly localized to the lower part of the outer ear (lp), the basal pinna zone (bp), craniofacial
210 mesenchyme (cm) and the proximal region of the mandibular prominence (pmp) (**Fig. 3g**).

211 In the LacZ assays assessing enhancer activity during mouse development, distinct patterns
212 emerged for each enhancer. For hEC1, no activity was observed at E9.5. However, by E11.5, strong
213 signals appeared in the proximal region of PA2, expanding to nearly the entire pinna, excluding the
214 upper distal region, by E14.5 (**Fig. 3h and Extended Data Fig. 4d**). In contrast, hEC2.1 displayed
215 only weak activity in the basal PA2 region and head at E9.5, with no detectable activity at later
216 timepoints (**Fig. 3i and Extended Data Fig. 4e**). For hEC2, weak activity was noted in the distal
217 PA1 and PA2 regions, head, and tail at E9.5. This activity persisted weakly in the distal PA2 region
218 and hindlimbs at E11.5, and in the proximal region of the mandibular prominence, head, and
219 hindlimbs at E14.5 (**Fig. 3j and Extended Data Fig. 4f**). hEC3 demonstrated two distinct patterns:
220 one exhibited partial activity in proximal PA2 and a small area below PA2 (1/5 of samples), while
221 the other showed activity in the limbs (4/5 of samples) (**Fig. 3l and Extended Data Fig. 4h**). These
222 results were somewhat similar to those using cellular models; thus, hEC2 appears to be active in
223 early CNCCs development in PAs, whereas hEC1 activity is initiated in CNCC-derived
224 mesenchyme stage in PAs, with both maintaining activity through craniofacial development.

225 To enable a detailed comparison between the spatial specificity of the *Hmx1* gene expression
226 at E11.5 and the LacZ staining patterns of three enhancers, we divided the *Hmx1* expression around
227 the PA2 zone into three distinct regions: α (proximal PA2 region), β (distal PA2 region), and γ
228 (caudal to PA2) (**Fig. 3g, right panel**). Our analysis elucidated the hierarchical relationship among
229 the three enhancers: hEC1 exerts a predominant influence on regions α and, to a lesser extent, γ ;
230 hEC2 is primarily associated with region β ; and hEC3 appears to affect region γ , albeit with an
231 inconsistent pattern. (**Fig. 3h, j, l**). This led us to hypothesize that hEC1, while driving significant
232 transcriptional activity, may not fully convey positional information. In contrast, hEC2 and hEC3,
233 despite their weaker transcriptional activities, could provide the additional positional information
234 required for precise *Hmx1* localization within the PA2 zone (intra-arch identity). To investigate this
235 particular gene patterning regulation, we constructed two additional vectors: hEC1+hEC2 and
236 hEC1+hEC2+hEC3, aiming to study the epistatic interactions among the enhancer cluster in the
237 BCE locus (**Fig. 3k and 3m**). Notably, the pattern exhibited by the hEC1+hEC2 combination was
238 distinct, showing reduced overall activity at E11.5 and a more defined spatial activity in the
239 frontonasal prominence (FNP) and limbs. Crucially, it modulated the spatial position within PA2
240 (**Fig. 3k and Extended Data Fig. 4g**), encompassing most *Hmx1* expression regions, including α ,
241 β , and part of γ (**Fig. 3k**). The hEC1+hEC2+hEC3 combination further extended this pattern, closely
242 mirroring the *Hmx1* spatial expression across regions α , β , and γ (**Fig. 3m and Extended Data Fig.**
243 **4i**). At E14.5, the staining pattern of hEC1+hEC2+hEC3 closely matched the spatial *Hmx1*
244 expression around the pinna region, especially in the lower pinna part adjacent to the proximal
245 mandibular region (**Fig. 3m**), correlating with areas of strong *Hmx1* expression (**Fig. 3g**).

246 These results indicate that spatial specificity of *Hmx1* expression around PA2 is finely tuned
247 by the coordinated and synergistic enhancers within an enhancer cluster, which we term the Position
248 Identity Hierarchical Enhancer Cluster (PI-HEC): hEC1 is responsible for most transcriptional
249 output, while hEC2 and hEC3 provide the supplementary positional information for the
250 transcriptional output.

251 **Regulatory dynamics of motif clusters within human EC1 responsible for activity and**
252 **specificity**

253 Although the three enhancers within the PI-HEC coordinately and synergistically regulate the
254 spatiotemporal expression characteristics of *Hmx1*, we also found that hEC1 possesses the dual
255 attributes of dictating the primary activity and proximal regional identity. Additionally, building on
256 our previous research with the orthologous mouse sequence (mEC1) of hEC1, which highlighted a
257 crucial 32 bp sequence regulated by the Hox-Pbx-Meis complex¹¹, we extended our analysis to
258 hEC1. To delve deeper into the regulatory dynamics, we targeted five motif clusters (D1, D2, D3,
259 D4, and D5 of hEC1), identified by TF-binding motif analysis using FIMO (**Fig. 4a and**
260 **Supplementary Table 3**). The impacts of deleting these individual clusters were evaluated using
261 both *in vitro* (PA-like hCNCCs) and *in vivo* (LacZ assay) methods.

262 *In vitro* luciferase assays showed that deletions of D2, D3, D4, and D5 significantly diminished
263 hEC1 activity, with D4 almost completely eliminating this activity (**Fig. 4b, top panel**). The *in vivo*
264 LacZ assay in mouse embryos revealed similar trends but also some notable differences (**Fig. 4b,**
265 **bottom panel**). The D1 deletion, while not affecting activity in the cell line, resulted in almost
266 complete loss of hEC1 activity in PA2 and other embryonic regions. Deletions of D2 and D5 led to
267 substantial reductions in staining, similar to the luciferase results (**Fig. 4b, bottom panel and**

268 **Extended Data Fig. 5a).** Interestingly, the D3 deletion, despite reducing activity *in vitro*,
269 maintained visible LacZ staining across the embryo, with a spatial shift in the PA2 region from
270 ventral to dorsal and ectopic PA1 staining. The D4 deletion eliminated staining throughout the
271 embryo, in accordance with the cell line luciferase results.

272 These observations emphasize the complex regulatory mechanisms that control both the
273 activity and specificity of the hEC1 enhancer. Concurrently, the distinct relationships of the five
274 motif clusters for the activity and spatial specificity of gene expression provide a valuable model
275 for elucidating the regulatory rules governing enhancers in pinna development¹³.

276 **hEC1 activity and specificity is coordinately controlled by multiple TFs**

277 To investigate the proteins that bind to hEC1, we performed *in vitro* DNA pull-down assays
278 using E11.5 PA2 tissue nuclear proteins and biotinylated hEC1 (**Extended Data Fig. 5b**). Proteomic
279 analysis via LS/MS (Liquid Chromatography-Mass Spectrometry) highlighted homeodomain TFs
280 (HD-TFs) such as Meis1, Pbx1/3, Dlx6 as the predominant hEC1-binding family of proteins
281 (**Extended Data Fig. 5c and Supplementary Table 4**). Considering the lower sensitivity of this *in*
282 *vitro* experiment and the prominence of a 'Coordinator' motif, a 17-bp long DNA sequence
283 encompassing basic helix-loop-helix (bHLH)- and HD-binding motifs in hCNCCs^{28,30}, we further
284 examined our motif prediction near the HD-TFs, and found that a pattern containing HD, high
285 mobility group (HMG) box and Coordinator (predicted with TWIST1 motif) sequences are present
286 in the D1 (DLX1-HD) and D3-D4 region (MEIS1/PBX1-HD) (**Fig. 4c and Supplementary Table**
287 **3**). Therefore, the discrepancy between the luciferase assay in the cell line and the transgenic LacZ
288 regarding the effect of D1 deletion on hEC1 activity may result from the difference in the *DLX* gene
289 family expression between these two systems (**Extended Data Fig. 3e**).

290 Here, we focus on the conserved D3-D4 region, containing three high-affinity binding sites (P
291 value $\leq 1E-04$) including MEIS1/PBX1, TCF7L1/2 and Coordinator and one low-affinity binding
292 site (P value $> 1E-04$) of ALX1/4, which are contained within the larger 76 bp duplications
293 associated with auricular malformations in sheep and cow microtia (**Fig. 4c**). To validate the TF-
294 binding events, we performed CUT&RUN assays in *in vitro* derived hCNCCs targeting TCF7L2
295 and reanalyzed one publicly available TWIST1 CUT&RUN dataset in hCNCCs³⁰, and confirmed
296 their binding capacity (**Fig. 4d and Extended Data Fig. 5d and 5e**). We then further applied
297 enhanced chromatin occupancy (EChO) analysis, which identifies TF interaction foci³¹, to explore
298 TCF7L2 binding patterns in the hEC1 region. One high-scoring motif was found in the D4 region,
299 consistent with the prediction result (**Fig. 4e and Supplementary Table 5**). The binding capacity
300 of human MEIS1 protein in hEC1 was also validated using the EMSA method (**Fig. 4f**).

301 We further constructed two deletion regions, D3-1 (including HD motifs) and D4-1 (including
302 HMG box and Coordinator motif) (**Fig. 4c**), with luciferase assay results demonstrating that removal
303 of D4-1 dramatically suppressed the activity of hEC1 (**Fig. 4g**). *Meis1*, *Tcf7l2*, *Twist1/Tcf4*, that
304 interacted with the D4-1 sequence, were all confirmed to be expressed in the PA2 region using
305 public mCNCCs bulk RNA-seq and WISH datasets (**Fig. 4h and i**). Collectively, these findings
306 suggest that the activity and specificity of hEC1 are modulated by a combination of different
307 families of TFs. The underlying regulatory code resides within the characteristics of the enhancer
308 sequences offers a complex process for pinna development.

309 **Impact of spatial *Hmx1* expression on pinna development: insights from transgenic mouse**
310 **models mimicking human BCE anomalies.**

311 To investigate human BCE development mechanisms, we created a transgenic mouse model,
312 *mEC1^{dup/dup}*, containing four copies of mEC1 sequences (**Fig. 5a, 5b and Extended Data Fig. 6a**).
313 LacZ reporter activity for mEC1 in the pinna region was similar to that of hEC1 but less intense
314 (**Fig. 3i, 5c and Extended Data Fig. 6b**). *mEC1^{dup/dup}* mice showed significant pinna development
315 abnormalities compared to wild-type (WT) mice (**Fig. 5d, 5e, 5g**). The helix of the pinna was notably
316 affected, with a reduced area (**Fig. 5e, 5f**), and the pinna angle changed, suggesting altered cartilage
317 or muscle formation (**Fig. 5g, 5h**). Older transgenic mice exhibited progressive eye dysgenesis,
318 though less consistent than ear malformations (**Extended Data Fig. 6c**). WISH showed spatially
319 expanded *Hmx1* expression in the PA2 region at E10.5 and in the upper pinna region at E14.5 in the
320 *mEC1^{dup/dup}* mice (**Fig. 5i, 5j**), well correlating with the activity of mEC1 (**Fig. 5c**). These findings
321 underscore the impact of enhancer copy number variation in developmental morphology, especially
322 in pinna formation.

323 To explore the interplay between EC1 and *Hmx1* expression in CNCCs in ear development, we
324 used multiple mouse models disrupting *Hmx1* function in various ways: *Wnt1::Cre;Hmx1^{fl/fl}*
325 (conditional *Hmx1* knockout in mCNCCs), *mEC1^{del/del}*, and *dumbo* (mutation in exon 1 of *Hmx1*
326 resulting in truncated protein after residue Gln65³²) (**Fig. 5k and Extended Data Fig. 6d**). The
327 pinna morphology in these models exhibits similar low set, laterally protruding characteristics (**Fig.**
328 **5k**), suggesting that mEC1 is crucial for proper *Hmx1* expression in mCNCCs and normal pinna
329 development. Finally, performing micro-CT analysis on all mouse models revealed that the normal
330 development of the paroccipital process, a conical prominence of bone adjacent to the outer ear and
331 serving as an attachment point for certain neck muscles, was inhibited in the *dumbo*,

332 *Wnt1::Cre;Hmx1^{fl/fl}* and *mEC1^{del/del}* mice but not in *mEC1^{dup/dup}* (Fig. 5I), which may be related to
333 the upright position (that is laterally protruding characteristics) of the external ear.

334 **EC1 duplication results in ectopic expression of *Hmx1*, leading to disrupted cell differentiation**
335 **in ear development**

336 To gain greater insight into the mechanisms underlying abnormal pinna development in the
337 *mEC1^{dup/dup}* mouse model, we performed bulk RNA sequencing at the E14.5 embryonic stage in the
338 whole pinna prominence (Fig. 6a). The duplication of the mEC1 led to overexpression of *Hmx1*,
339 but the majority of differentially expressed genes (DEGs) were downregulated. This suggests that
340 increased expression of *Hmx1* plays a critical role in suppressing numerous genes during pinna
341 development (Fig. 6a and Supplementary Table 7). Gene Ontology (GO) enrichment analysis of
342 these downregulated DEGs showed their primary involvement in pathways essential to ear
343 development, such as epidermis development, extracellular collagen organization, and myofibril
344 assembly (Fig. 6b and Supplementary Table 8). In addition, two cartilage development-related
345 genes *Comp* and *Arhgap36* were also downregulated, although they did not rank high in the GO
346 enrichment analysis (Fig. 6a and 6b). Masson's trichrome staining at E14.5 revealed delayed
347 development of muscle and epidermis in the outer ear of *mEC1^{dup/dup}* mice compared to that in wild-
348 type mice, consistent with the bulk RNA-seq results (Fig. 6c). However, *Hmx1* is typically
349 expressed in the craniofacial mesenchyme, which is not a source for muscle and epidermis in the
350 pinna³³. Thus, in conjunction with the WISH results (Fig. 5j), we hypothesize that the defects
351 observed in the outer ear are due to ectopic expression of *Hmx1* in other pinna zones.

352 To definitively characterize the cell types expressing the *Hmx1* gene within the outer ear, and
353 to further elucidate the molecular mechanisms involved in BCE, single-cell lineage tracing was

354 employed in *Hmx1*-P2A-GFP mice at pivotal developmental stages: E10.5, E12.5, and E14.5

355 (**Extended Data Fig. 7a**). Primarily, the *Hmx1*⁺ cells were identified as fibroblasts, with a small

356 fraction defined as other cell types including neurons, myogenic cells, and chondrocytes also

357 detected (**Fig. 6d and Extended Data Fig. 7b**). The fibroblasts were further categorized into seven

358 subtypes based on distinct marker genes. These include skeletal muscle-related fibro (*Ogn*, *Mest*)³⁴,

359 two fibro-adipogenic progenitors (*Enpp2*⁺, *Osr1*⁺)^{35,36}, dermal fibro progenitors (upper: *Crabp1*,

360 *Twist2*; lower: *Malat1*, *Meg3*)³⁷, miotic CNCC-derived mesenchymal cells (*Ube2c*, *Top2a*)³⁸, and

361 perimysial cells (*Dcn*, *Lum*)³⁴ (**Fig. 6e and Extended Data Fig. 7c**). In the developmental trajectory

362 analysis with the cluster of CNCC-derived mesenchymal cells (C6) as the root, we demonstrated

363 that it has the potential to differentiate into the other six fibroblast-related cell clusters (C1, C2, C3,

364 C4, C5, C7) (**Fig. 6f**), suggesting an important role of the *Hmx1* gene on pinna fibroblast

365 development. We further noticed that genes that were substantially downregulated ($\log FC > 1$) in

366 *mEC1*^{dup/dup} mice were predominantly not expressed in *Hmx1*⁺ cells of WT mice, substantiating our

367 earlier hypothesis that ectopic *Hmx1* expression suppresses cell fate differentiation (**Fig. 6g**).

368 To provide conclusive evidence for our hypothesis that defects in the outer ear are attributable

369 to aberrant *Hmx1* expression, *in situ* section RNA hybridization (*Hmx1*, *Dmkn*) was performed on

370 both upper and lower sections of the pinna in wild-type and *mEC1*^{dup/dup} mice. The results

371 demonstrated upregulated expression of *Hmx1* gene in the basal pinna zone, and more notably, an

372 expansion of *Hmx1* expression from the basal pinna zone to the distal tip of the pinna, coupled with

373 a downregulation of *Dmkn* expression in these areas (**Fig. 6h and 6i**), which may result from a non-

374 cell autonomous effect of *Hmx1* expression on the tissue adjacent to the epidermis. Taken together,

375 our data provide strong evidence for the critical role of *Hmx1* in the observed abnormalities in the
376 outer ear.

377

378 **Discussion**

379 This study examines the genomes of seven human pedigrees, whose members present with
380 constricted ears. All affected individuals showed a duplication of a genomic region termed the BCE
381 locus near the *HMX1* gene. We present compelling evidence that the duplication of regulatory
382 elements in the BCE locus erroneously modulates the spatiotemporal expression characteristics of
383 *HMX1*, leading to the ear developmental abnormality.

384 The evolutionarily conserved region (ECR) downstream of *Hmx1* has been implicated in eye
385 and external ear malformations across multiple species^{8,9,11}, and linked to human isolated bilateral
386 concha-type microtia¹⁰. However, the explicit pathogenic mechanism in BCE patients remained
387 unclear. This uncertainty was due to observations of larger genomic duplications extending beyond
388 the single ECR element in previously reported pedigrees¹⁰ and in our seven newly analyzed
389 pedigrees. We have identified a minimal critical region, the 'BCE locus', encompassing three distinct
390 cis-regulatory elements. We demonstrate that this locus is the causative factor for bilateral
391 constricted ear by employing transgenic cell and mouse models. In many CNV-related
392 developmental abnormalities, distinct cis-regulatory elements are organized as a cluster in the
393 mutation interval^{12,25,27}. The deletion or duplication of these elements induces morphological
394 variations, stemming from differential gene expression^{12,39}. Our mouse models reveal that the
395 morphology of the pinna is particularly sensitive to changes in *Hmx1* gene expression due to
396 variation in the copy numbers of enhancer sequences. Therefore, the pinna morphology variation
397 among pedigrees may also be caused by a different number of cis-regulatory elements within the
398 associated CNV or distinct interaction patterns between these elements and the *Hmx1* promoter,

399 which may require the study of patient-specific hiPSCs²⁷ for further analysis. Alternatively, this
400 variation may reflect the contribution of other family-specific genetics variants.

401 Enhancers activated within specific developmental windows are crucial for normal craniofacial
402 development, as evidenced by the study of long-range enhancer clusters in hCNCCs in the PRS
403 locus²⁵ and inter-TAD interactions controlling *Hoxa* function^{22,26}. Our results also demonstrate that
404 the enhancers in the BCE locus are activated at different developmental stages of hCNCCs: hEC2
405 may be activated at early hCNCCs stage, and hEC1 is activated at late- and PA-like hCNCCs stage
406 (**Fig. 7a**). The anterior-posterior positional identity of gene expression in CNCCs is pivotal for
407 craniofacial development¹⁷. Likewise, optimizing the proximo-distal positional identity within the
408 same pharyngeal arch is equally crucial¹⁸. In this study, we elucidate the mechanism of *Hmx1* gene
409 patterning related to both the enhancer and motif cluster sequences. We have delineated an intra-
410 arch positional identity enhancer cluster, named PI-HEC. Redundancy within clusters of enhancers,
411 or within super enhancer (SE) regions, is a prevalent phenomenon that has been observed in multiple
412 genomic loci⁴⁰, providing phenotypic robustness^{41,42}, buffering gene expression against mutations⁴³
413 and transcriptional noise⁴⁴. Similar additive effects of a multipartite enhancer cluster have also been
414 reported in the *Ihh* locus¹². Besides these two modes, synergy (super-additive) of different enhancers
415 is also observed in the EC1.45 of the PRS locus²⁵, the *Fgf5* locus⁴⁵, and regulating gap gene-
416 expression patterns in *Drosophila* embryos⁴⁶ and coordinating cell fate determination⁴⁷. Compared
417 with aforementioned interaction modes of multipartite enhancers, the PI-HEC presents a distinct
418 scenario in which they possess both coordinated and synergistic properties: hEC1 serves as the
419 primary transcriptional activity driver in the proximal region, hEC2 enhances transcription weakly
420 but contributes distal positional information, and hEC3 alone is a weak, unstable enhancer but

421 compensates caudal positional information and becomes stable when combined with hEC1 and
422 hEC2 (**Fig. 7b**). This collaborative mode is somewhat similar to the interaction between
423 predominant sites and supportive sites studied in the estrogen receptor alpha binding sites (ERBS)⁴⁸
424 and recently reported non-classical enhancers (facilitators) in the mouse *α-globin* cluster⁴⁹. However,
425 this study present, for the first time, the synergistic and coordinated effects of multipartite regulatory
426 elements on the spatial regulation of gene expression in a disease-related locus. The underlying
427 mechanism for this pattern may be explained by the spatial proximity of these enhancers. In this
428 case, TFs or coactivators, responsible for driving transcription, recruited to hEC1 can spread to
429 hEC2 and hEC3^{50,51}. However, this possibility needs to be further investigated in its original three-
430 dimensional genomic context⁵². Furthermore, whether this new mode of interplay between
431 multipartite enhancers is a common phenomenon in the regulation of intra-arch gene patterning in
432 CNCCs also requires further exploration, but it potentially signifies a paradigm shift in our
433 understanding of multipartite enhancers or SE dynamics⁵³.

434 The molecular basis of gene patterning is predominantly shaped by the interaction between
435 tissue-specific TFs and enhancer structural organization^{13,51,54-56}. While enhancers have been
436 extensively studied for their role in governing spatial gene expression at embryonic level^{12,25,57-60}
437 and across branchial arches⁶¹, the precise mechanisms dictating gene expression within intra-arch
438 regions remain unclear. Our investigation into the spatial specificity of *Hmx1* expression highlights
439 that gene patterning within specific sub-structures, such as the PA2 zone, is regulated by the highly
440 restricted activity of enhancers. We have uncovered the vital role of TALE-type HD TFs, HMG box-
441 containing TFs and Coordinator-related TFs (TWIST1) in their interaction with hEC1, a key element
442 for its functional integrity. TALE-type HD TFs are critical for the formation of the PA2 ground

443 state⁶², and our study also suggests a functional involvement in maintaining the proximal spatial
444 position of hEC1. TCF7L2, a TF newly identified in this study as binding to hEC1, and the
445 Coordinator motif in the D4 region, are both crucial for the activity of hEC1 (**Fig. 7c**). TCF7L2 is a
446 Wnt signaling effector, modulating the neural crest gene expression in a position-dependent
447 manner⁶³; whereas the Coordinator motif, which can be bound by many bHLH and HD TFs, are
448 important for shaping facial morphology³⁰. Our study on the hEC1 structural arrangement further
449 revealed that a novel coordinator pattern, consisting of HD, HMG-box and Coordinator motifs (in
450 the D1 and D3-D4 regions), is crucial for enhancer activity and specificity. Whether these new
451 regulatory rules exist in other craniofacial-specific enhancers remain to be investigated.

452 Duplication of genomic sequences, particularly those containing enhancers, can lead to neo-
453 TAD formation at the *SOX9* locus and *KCNJ2* misexpression⁶⁴, precipitate ectopic gene expression¹²,
454 resulting in limb malformations, and even contribute to lung adenocarcinoma⁶⁵. Specifically, the
455 duplication of hEC1 also disrupts the spatial specificity of *Hmx1* expression, contributing to
456 aberrations in the proximal helix and scapha in mice. These regions mainly originate from neural
457 crest-derived mesenchymal cells^{33,66,67}, which aligns with our scRNA-seq data and underscores the
458 pivotal role of *Hmx1* in the normal development of CNCC-derived fibroblasts in the outer ear (**Fig.**
459 **7d**). CNCC-specific knockout of *Hmx1* in mice leads to a low-set, protruding ear phenotype,
460 consistent with findings in mEC1 deletion mice and 'dumbo' mice³². This suggests that appropriate
461 *Hmx1* expression in CNCCs is essential for pinna organogenesis⁷, further substantiating the validity
462 of employing CNCCs as a cellular model for the investigation of BCE pathogenesis. Notably, the
463 ear malformations observed in most human BCE patients within our study pedigrees are more severe
464 than those in our *mEC1^{dup/dup}* mouse model. This discrepancy may arise from a broader expansion

465 of *Hmx1* expression due to the extent of the duplication of the PI-HEC region, rather than solely the
466 hEC1 duplication¹². Despite these differences, the phenotypic hallmarks of the *mEC1^{dup/dup}* mouse,
467 including reduced ear area and a wrinkled helical rim, do grossly mimic the ear phenotype observed
468 in patients.

469 In summary, our results reveal that CNCC-specific and precise spatial specificity of *Hmx1*
470 expression is vital for the development of fibroblasts in the outer ear, with both loss and gain of
471 *Hmx1* expression contributing to pinna malformation. The gene patterning of *Hmx1* across PA2 is
472 intricately modulated by hEC1, hEC2, and hEC3, with hEC1's dominance as an enhancer being
473 further refined by coordinator motif-transcription factor binding events. Our study reveals the
474 complex interplay of gene regulatory activity in precise developmental space and time, and
475 contributes to the understanding of the regulatory rules of gene expression.

476 **Methods**

477 **Ethics statement.** All procedures involving human samples were performed with the approval of the Ethics

478 Committees of the School of Biological Science and Medicine Engineering at Beihang University (BM20210057)

479 and the Plastic Surgery Hospital of the Chinese Academy of Medical Sciences (2017-07). The study has been

480 registered and approved by China's Ministry of Science and Technology (project 2023-CJ0849). Written informed

481 consent for participation in genetic and biological research was obtained from all subjects or their legal guardians.

482 Consent for the publication of photographs was given after a separate explanation and request. All animal

483 experiments were performed under the approval of the Animal Care Committee at Beihang University

484 (BM20210057).

485 **Samples and recruitment.** We recruited members of seven Chinese families (from five separate provinces) in which

486 bilateral constricted ear was segregating in a Mendelian fashion. The phenotype in all pedigrees segregated in a

487 manner consistent with autosomal dominant inheritance. All affected subjects presented with a bilateral constricted

488 ear phenotype, as shown in both ears of the probands in Fig. 1B. This phenotype is characterized by a malformation

489 of the external ear, notably reduced size of the helix and absence of the triangular fossa, scaphoid fossa, and antihelix,

490 giving a shell-like appearance. Contrastingly, the crus helicis, concha cavity, tragus, and earlobe maintained their

491 normal structure. No accompanying facial abnormalities were observed.

492 **Genotyping, target-capture sequencing, and whole-genome sequencing.** We extracted DNA from venous blood

493 samples using the TIANamp DNA Midi Kit (Tiangen Biotech, Beijing, China). Genotyping was performed on 40

494 samples using the Human Omni-Zhonghua chips (Illumina, CA, USA) for pedigrees 1, 2, 3, 4, 6, and 7. Target-

495 capture sequencing was conducted on 32 samples from pedigrees 1, 3, and 7 using the Agilent SureSelect Kit

496 (Agilent Technologies, Santa Clara, CA, USA). Whole-genome sequencing was carried out for the proband of

497 Pedigree 5 using the DNBSEQ-T7 platform (Huada, Shenzhen, China).

498 For the chip data, we utilized the Genotyping and CNVPartition modules of GenomeStudio v2011.1 for
499 genotype and CNV calling, achieving genotype call rates above 99.6%. The target-capture sequencing involved
500 designing capture oligos for a 5.9Mb region encompassing the susceptible locus using the SureDesign tool (Agilent
501 Technologies, Santa Clara, CA, USA). The DNA library was prepared following the manufacturer's specifications,
502 and sequencing was executed on the Illumina HiSeq X10 system (Illumina, San Diego, CA, USA), yielding an
503 average depth of 196X per sample.

504 Quality control for next-generation sequencing data was conducted using FastQC v1.1.0 and Cutadapt v1.15.
505 Post quality control reads were mapped to the human reference genome (hg38) using BWA v0.7.16a⁶⁸. PCR
506 duplications were removed with Picard v2.27.0, and BAM file sorting and indexing were performed using Samtools
507 v1.18. SNP and small indel calling were done using the HaplotypeCaller model of GATK v4. For identifying causal
508 variants, we applied criteria including cosegregation with affected and unaffected individuals in each pedigree, minor
509 allele frequency below 0.05 in dbSNP138, ExAC project, and the 1000 Genomes database, and minimum coverage
510 depth of 20 with an alternative allele depth above 5.

511 **Causal mutation screening.** Our screening for causal mutations began with linkage analysis to pinpoint the
512 suspected genomic locus for bilateral isolated constricted ear. We adhered to the quality control (QC) procedures
513 outlined by Mao *et al.* for pruning SNPs in strong linkage disequilibrium, removing SNPs with Mendelian errors,
514 and verifying sex specifications¹⁵. Parametric multi-point linkage analysis was conducted on Pedigrees 1, 3, and 7,
515 both individually and collectively, using MERLIN v.1.1.2⁶⁹. For consanguinity analysis, we used the same QC-
516 approved data and performed pairwise IBD estimation for founders from the seven pedigrees using Plink v1.9⁷⁰. A
517 PI-HAT value greater than 0.1 between paired founders indicated a genetic relationship.

518 After examining all mutations within the coding region of the target area, we assessed copy number variations
519 using differential coverage depth. We utilized the 'getSegmentReadCountsFromBAM' function in cn.mops for read

520 coverage of genomic segments⁷¹. To detect CNVs, the read count matrix was normalized for each base relative to
521 the mean coverage of the target-capture regions. We excluded segments with an average read count below 90 to
522 minimize noise from untargetable regions. This threshold was based on the theoretical depth in cases where a deletion
523 was homozygous in 22 sequenced cases and heterozygous in 10 controls, given a mean depth of 196 for target
524 regions. We then calculated and displayed the ratio of the average read count of cases to controls for each family.
525 Furthermore, to illustrate the CNV of each case at the target-capture region, we calculated and plotted the case-to-
526 control read count ratio for each family (Supplementary Fig. 1C). The expected ratios for CNV=3, CNV=2, and
527 CNV=1 were approximately 1.5, 1, and 0.67, respectively.

528 **Culture of human embryonic stem cells (hESCs).** Female H9 (WA09) hESCs were cultured on six-well plates
529 pre-coated with hESC-qualified Matrigel matrix (Corning, catalog no. 354277). The cells were maintained in mTeSR
530 media (Stem Cell Technologies, catalog no. 85850), which was replenished daily. For routine passaging every 4-6
531 days, hESC were diluted at ratios between 1:6 and 1:50 using 0.5 mM EDTA-PBS (Thermo Fisher Scientific, catalog
532 no. 15575020).

533 **Generation of CRISPR/Cas9 genome-edited cell lines.** For the deletion of specific regions in H9 hESCs via
534 CRISPR/Cas9, six guide RNA (gRNA) sequences targeting the hEC1 and hEC2 regions (approximately 9 kb) were
535 designed based on sequences from the Ensembl Genome Browser (Extended Data Fig. 4a). The gRNA sequences
536 were as follows: g2 - CCAGACCCCTATGGAGCACGGGG, g4 - GCGGATCCAAGCTCACCTCAGG, g5 -
537 CGATCTTAGTGCCTCACCGCGG, g6 - GGGGTATTCTGCTGGCCGTAGGG, g1 -
538 AGGAGTGTAGGAGCCGATGGTGG, and g3 - TCTGCTGTGACTCACGGTTGAGG. Confluent hESC colonies
539 were dissociated into a single-cell suspension, and 3.0×10^6 cells were electroporated using the P3 Primary Cell 4D-
540 Nucleofector L kit and 4D-Nucleofector system (Lonza Group Ltd., Basel, Switzerland), following the
541 manufacturer's protocol (1320v, 30ms, 2 pulses). Post-transfection, the cells were plated in 6-well plates using

542 mTeSR media supplemented with 10 μ M Y-27632 (Stem Cell Technologies, catalog no. 72304) for 48 hours. Cells
543 with high viability were then selected in media containing puromycin (1 μ g/ml) for 2-3 days. Drug-resistant wells
544 were subsequently processed for single-cell isolation using Accutase (Sigma-Aldrich, catalog no. A6964), diluted,
545 and re-plated into a 96-well plate. Pool cleavage efficiency was assessed using the EZ-editor Genotype Analysis
546 System (UBIGENE). After two weeks, colonies were picked, split, and screened for enhancer deletion using
547 specifically designed primers (Extended Data Fig.4a and Supplementary Table 2). Positive clones with confirmed
548 homozygous deletions were expanded and prepared for cryopreservation for downstream analysis.

549 **hCNCCs and PA-like hCNCCs derivation and culture.** hESCs were differentiated into cranial neural crest cells
550 (hCNCCs) following a previously described protocol with minor modifications²⁸. Initially, confluent hESC colonies
551 were treated with 2 mg/mL collagenase (Gibco, catalog no. 17104019) for 30-60 minutes until colony edges began
552 to lift. These detached colonies were then cultured in neural crest cell induction (NCCI) medium, forming clusters
553 of 100-200 cells in ultra-low attachment petri dishes. The NCCI medium comprised a 1:1 mixture of DMEM F-12
554 medium (Thermo Fisher Scientific, no. 10565018) and Neurobasal medium (Thermo Fisher Scientific, no.
555 21103049), supplemented with 0.5 \times N2 (Thermo Fisher Scientific, no. 17502048), 0.5 \times B27 (Thermo Fisher
556 Scientific, no. 17504044), 20 ng/mL bFGF (Peprotech, catalog no. AF-100-18B), 20 ng/mL EGF (Peprotech, catalog
557 no. AF-100-15), and 5 μ g/mL bovine insulin (Gemini Bio, catalog no. 700-112P). After about 24 hours, embryoid
558 bodies (EBs) formed and were maintained with bi-daily changes of NCCI medium. On day 4, EBs were transferred
559 to new tissue culture treated dishes for approximately three days to initiate sphere attachment. Following attachment,
560 media was changed daily, allowing cranial neural crest cells to migrate from the neural rosettes over about four days.
561 Neuroepithelial spheres were then manually removed, and the remaining neural crest cells were harvested and
562 passaged onto fibronectin (7.5 μ g/mL)-coated plates (Millipore, catalog no. FC010-100MG) in early hCNCCs
563 medium. This medium included a 1:1 DMEM F-12/Neurobasal mixture, 0.5 \times N2 supplement, 0.5 \times B27 supplement,

564 20 ng/mL bFGF, 20 ng/mL EGF, 1 mg/mL BSA (Gemini Bio, catalog no. 700–104 P), and 1× antibiotic-antimycotic
565 (Gibco, catalog no. 15240062). After two additional passages, the medium was changed to late hCNCCs medium by
566 supplementing the early hCNCCs medium with 3 μ M CHIR 99021 (Selleckchem, catalog no. S2924) and 50 pg/mL
567 BMP2 (Peprotech, catalog no. AF-120-02) to enhance cell proliferation and reduce migration²⁸. Following two more
568 passages, late-stage hCNCCs were induced to transition into pharyngeal arch (PA)-like cell states by adding 100 nM
569 retinoic acid (RA) (Sigma-Aldrich, catalog no. R2625) to the late hCNCCs medium for additional two passages.

570 **Immunofluorescence analysis.** hCNCCs were cultured on fibronectin-coated (7.5 μ g/mL) coverslips placed in 6-
571 well plates. Upon reaching confluence, cells were fixed with 4% paraformaldehyde (PFA) for 10 minutes at room
572 temperature and permeabilized with 0.1% Triton X-100 in PBS for 15 minutes. The cells were then incubated with
573 primary antibodies targeting p75 (Abcam, catalog no. ab245134), NR2F1 (Abcam, catalog no. ab181137), AP2
574 (Santa Cruz Biotechnology, catalog no. sc-12726), and SOX9 (Millipore, catalog no. AB5535), each diluted in
575 blocking buffer, and left overnight. After washing thrice for 5 minutes each with PBS, the cells were incubated for
576 1 hour in the dark with anti-mouse Alexa Fluor 488 antibody (Thermo Fisher Scientific, catalog no. A28175) and
577 anti-rabbit Alexa Fluor 594 antibody (Thermo Fisher Scientific, catalog no. A-11012). Following another series of
578 three 5-minute washes in PBS, the coverslips were mounted on slides using DAPI Fluoromount-G (SouthernBiotech,
579 catalog no. 0100-20). Imaging was performed on a Carl Zeiss LSM 980 microscope, and the acquired images were
580 processed using ImageJ software.

581 **RNA extraction, cDNA preparation, and quantitative real-time PCR.** For each of the three independent hCNCCs
582 differentiation experiments, approximately 2×10^6 cells per well were washed with cold PBS and lysed using Buffer
583 RLT (Qiagen, catalog no. 79216). RNA extraction was performed according to the manufacturer's protocol (RNeasy
584 Mini Kit, Qiagen, catalog no. 74104). Subsequently, 1-2 μ g of total RNA from each sample was reverse transcribed
585 to cDNA using RevertAid H Minus Reverse Transcriptase (Thermo Fisher Scientific, catalog no. EP0452). The

586 resulting cDNA samples were diluted, and qRT-PCR was conducted on a Bio-Rad CFX96 real-time PCR machine
587 using SYBR Green PCR Master Mix (Thermo Fisher Scientific, catalog no. 4309155), following the manufacturer's
588 instructions. The delta-delta Ct method was employed to calculate the relative expression levels.

589 **Promoter-Capture Hi-C in late hCNCCs.** The preparation of Promoter Capture Hi-C libraries was conducted
590 following established protocols^{72,73}. Cells were first fixed with 2% formaldehyde for 10 minutes at ambient
591 temperature, followed by quenching with 0.2M glycine for 5 minutes. Post-fixation, cells were lysed, and
592 endogenous nucleases were inactivated with 0.3% SDS. Chromatin was digested using 100U of HindIII (New
593 England Biolabs, catalog no. R0104L), labeled with Biotin-14-dCTP (Invitrogen, catalog no. 19518018), and then
594 ligated using 50U of T4 DNA ligase (New England Biolabs, catalog no. M0202L). After reversing the cross-links,
595 DNA was isolated using the QIAamp DNA Mini Kit (Qiagen, catalog no. 51306), in strict accordance with the
596 manufacturer's instructions. Subsequent steps involved fragmenting the DNA to 300-600 bp, end-repair, A-tailing,
597 and adapter ligation using SureSelect adaptors. Biotinylated fragments were isolated through streptavidin-affinity
598 pull-down and PCR amplified. Promoter-specific Capture Hi-C was performed using the SureSelect XT Library Prep
599 Kit ILM (Agilent Technologies), which included a custom-designed biotinylated RNA bait library and paired-end
600 blockers. Post-capture PCR enrichment was followed by final purification of the libraries with AMPure XP Beads
601 (Beckman Coulter, catalog no. A63881). Library quality was evaluated using Bioanalyzer profiles (Agilent
602 Technologies), and high-throughput sequencing was performed on the Illumina NovaSeq 6000 platform.

603 **Luciferase assay.** The luciferase assay was conducted as previously described²⁵. In the case of hESCs, small clusters
604 of 4-10 cells each were passaged into a 24-well plate with ROCK inhibitor (Y27632), and transfection was performed
605 the following day. For pharyngeal arch-like hCNCCs, cells were transfected two hours post-seeding at approximately
606 160,000 cells per well in 24-well plates. Each assay consisted of four technical replicates. The transfection mix
607 included 0.5 µg of pGL3-enhancer plasmids with firefly luciferase gene sequences driven by an SV40 promoter

608 (Promega, catalog no. E1761), 0.02 µg of pRL-TK Renilla luciferase (Promega, catalog no. E2261) as an internal
609 control, and 1.5 µL of FuGENE HD (Promega, catalog no. E2691), all diluted in Opti-MEM I Reduced-Serum
610 Medium (Gibco, catalog no. 31985062). The enhancer sequences were cloned into the cut site between KpnI and
611 XhoI, and relevant plasmid construction primers are listed in Supplementary Table 2.

612 Twenty-four hours post-transfection, cells were harvested for measurement using the Dual-Luciferase Assay
613 System (Promega, catalog no. E4550), following the manufacturer's instructions, on a CLARIOstar Plus machine
614 (BMG LABTECH). Two or three independent biological replicates were conducted, and the relative firefly luciferase
615 activity was calculated by normalizing the firefly signal values to the renilla signal values across the reaction period.

616 **Enhancer-reporter assays in mouse embryos.** Human enhancer sequences (hEC1-chr4: 8700174-8700974;
617 hEC2.1-chr4: 8705075-8706475; hEC2-chr4: 8705075-8706475; hEC3-chr4: 8725074-8725674, hg38 version)
618 were synthesized or PCR-amplified from H9 cell line genomic DNA. Combinations of these sequences, including
619 (hEC1+hEC2) and (hEC1+hEC2+hEC3), along with deletion tiling variants of hEC1 (Δ D1- Δ D5), were assembled
620 using NEBulider HiFi DNA Assembly Mix (New England Biolabs, catalog no. E2621L). These constructs were then
621 cloned into PCR4-Shh:LacZ-H11 plasmids (Addgene plasmids, #139098), placing them upstream of a minimal *Shh*
622 promoter and LacZ reporter gene. Similarly, the orthologous mouse enhancer, mEC1 (chr5: 35623357-35624110,
623 mm39 version), was amplified from C57BL/6J mouse genomic DNA and cloned using the same method. The
624 detailed primers used are in the Supplementary Table 2.

625 CRISPR/Cas9 microinjection protocol was employed to site-specifically integrate these enhancer sequences
626 into the H11 locus of the FVB mouse strain, which served as surrogate mothers. F₀ embryos were harvested at
627 developmental stages E9.5, E11.5, and E14.5. Only embryos carrying the transgenic reporter at the H11 locus were
628 processed further for LacZ staining. Genotyping primers for each construct are listed in Supplementary Table 2.
629 Whole mouse embryo LacZ staining was performed as previously established protocols⁷⁴. For each enhancer and

630 developmental timepoint, a minimum of three independent positive embryos were analyzed. Imaging was conducted
631 using a Carl Zeiss Axio Zoom V16 microscope.

632 **Enhancer DNA pull-down assay.** Biotin-labeled enhancer DNA sequences were prepared via PCR and verified
633 through 1% agarose gel electrophoresis. Approximately 50 mouse embryos at E11.5 were microdissected to isolate
634 PA2 tissues, which were then washed with cold PBS and homogenized using a Dounce homogenizer. Nuclear
635 proteins were extracted using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific,
636 catalog no. 78833), following the manufacturer's protocol. Protein concentrations were quantified using a BCA
637 protein assay kits (Thermo Fisher Scientific, catalog no. 23225).

638 The DNA probe and nuclear proteins were pre-mixed and incubated with Bioeast Mag-SA (Streptavidin, SA,
639 Bioeast, catalog no. M2800S) for 1 hour at 4°C. The magnetic beads were then isolated using a magnetic stand and
640 washed thrice with cold PBS. The eluted proteins were analyzed by SDS-PAGE and silver staining to confirm
641 binding. Finally, protein identification was performed using liquid chromatography-mass spectrometry (LC-MS).

642 **CUT&RUN experiment in hCNCCs.** The CUT&RUN assay was conducted in hCNCCs using the
643 ChIC/CUT&RUN Kit (Epicypher, catalog no. 14-1048), incorporating several modifications from previously
644 reported methods. Approximately 500,000 cells were harvested using Accutase and subsequently incubated with
645 activated ConA Beads for 10 minutes at room temperature. Primary antibodies were then added to each 50 µL
646 reaction: IgG (Epicypher, catalog no. 13-0042k, 0.5 µg), H3K27ac (Active Motif, catalog no. 39133, 0.5 µg),
647 TCF7L2 (Cell Signaling, catalog no. 2569S, 1 µg), and the mixture was incubated overnight on a nutator at 4°C.

648 On the second day, pAG-MNase and cold calcium chloride were used to activate the cleavage of target DNA.
649 E. coli Spike-in DNA (0.1 ng) was also added for normalization in downstream analyses. DNA purification involved
650 phenol/chloroform extraction and ethanol precipitation. Library preparation for histone proteins was performed
651 using the CUT&RUN Library Prep Kit (Epicypher, catalog no. 14-1001). For TFs, modified procedures, as

652 previously reported (<https://doi.org/10.17504/protocols.io.bagaibse>), were employed to enhance the preservation of
653 small DNA fragments. Sequencing was carried out using paired-end reads (2 × 150 bp) on the Illumina NovaSeq
654 6000 platform.

655 **Expression of recombinant proteins and electrophoretic mobility shift assays (EMSA).** The coding sequences
656 for MEIS1 protein was cloned into the pET-His6-MBP-TEV-LIC vector between BamHI and XhoI sites,
657 incorporating a tobacco etch virus (TEV) protease cleavage site (ENLYFQ|G) between the maltose-binding protein
658 (MBP) and the MEIS1 protein. BL21 (DE3) competent cells were transformed with this construct. Positive bacterial
659 cultures were grown at 37°C until the optical density at 600 nm (OD600) reached 0.5 and then induced with 0.2 mM
660 isopropyl β-D-1-thiogalactopyranoside (IPTG). Bacterial cells were lysed by sonication in buffer A (50 mM Tris-
661 HCl, 500 mM NaCl, 10 mM 2-mercaptoethanol, 10% (v/v) glycerol, pH 7.5) and centrifuged to collect the
662 supernatant. This supernatant was then applied to a Ni-NTA Superflow Cartridge (Sangon, catalog no. C600792),
663 washed with buffer A supplemented with 50 mM imidazole, and eluted with an imidazole gradient from 100 mM to
664 500 mM in buffer A. The eluted protein was treated with TEV protease and dialyzed overnight in buffer A at 4°C.
665 The protein mixture was re-applied to a Ni-NTA Superflow Cartridge and eluted with buffer B (50 mM Tris-HCl, 1
666 M NaCl, 10 mM 2-mercaptoethanol, 10% (v/v) glycerol, pH 8.0) containing 50 mM imidazole. Finally, the MBP-
667 free protein was further purified using size-exclusion chromatography (Superdex 200 Increase 10/300 GL; Cytiva,
668 catalog no. 28990944) and concentrated to approximately 1 mg/mL in buffer C (50 mM Tris, 200 mM NaCl, 10 mM
669 2-mercaptoethanol, 10% (v/v) glycerol, pH 7.5).

670 EMSA was performed using the LightShift Chemiluminescent EMSA kit (Thermo Fisher Scientific, catalog no.
671 20148) with the purified TF protein. Biotin-labeled probe containing predicted MEIS1-binding DNA sequence was
672 synthesized and incubated with the MEIS1 following the manufacturer's protocol. The resultant gels were visualized
673 using a Tanon 5200 system.

674 **Generation of genome-edited mouse models via CRISPR/Cas9.** This study utilized four distinct mouse models
675 constructed using the CRISPR/Cas9 technique: mEC1 deletion (*mEC1*^{del/+}), mEC1 duplication (*mEC1*^{dup/+}), *Hmx1*^{fl/+},
676 *Hmx1*^{wt/EGFP}. gRNAs were designed using CHOPCHOP to target specific regions: *mEC1*^{del/+}:
677 AGGACAGTCTCCAAGTCCGG-TGG; *mEC1*^{dup/+}: TGTGACGTGATCGACTCCAT-CGG; *Hmx1*^{fl/+}: gRNA1-
678 CCCAGATTCAAGGCGTACAA-GGG, gRNA2- ACTGACTTGTTCCTACCTAC-AGG; *Hmx1*^{wt/EGFP}: gRNA1-
679 ATGCCGGGGCTAGTGTGAGC-CGG, gRNA2-GCGCCGGCTCACACTAGCCC-CGG. A combination of
680 sgRNAs, Cas9 protein, and donor vectors were co-injected into fertilized mouse embryos at the single-cell stage. F0
681 founder mice were identified via PCR and confirmed by Sanger sequencing. These founders were bred with wild-
682 type mice for germline transmission testing and F1 heterozygous mouse generation. Different homozygous
683 genotypes were subsequently produced by intercrossing heterozygous mice.

684 The generation of *Wnt1-Cre*, *ROSA26-CAG-LSL-tdTOMATO* and *dumbo* mouse lines has been previously
685 described¹¹. *Wnt1::Cre;Hmx1*^{fl/fl} mice were generated by crossing *Wnt1::Cre;Hmx1*^{fl/+} male mice with *Hmx1*^{fl/fl}
686 female mice, and the offspring were validated using PCR. *Wnt1::Cre;Rosa26*^{tdTomato/+}*;Hmx1*^{EGFP/wt} bicolor
687 fluorescent mice were generated by initially crossing *Hmx1*^{EGFP/wt} male mice with *Rosa26*^{tdTomato/+} female mice to
688 produce *Rosa26*^{tdTomato/tdTomato}*;Hmx1*^{EGFP/EGFP} mice, which were then crossed with *Wnt1-cre* mice to yield the final
689 model. All mice were maintained on a C57BL/6J genetic background, housed in a Specific Pathogen Free (SPF)
690 environment, and handled according to ethical standards. These mouse lines are available upon request from the
691 corresponding author.

692 **Sample preparation, RNA isolation and bulk RNA-seq library preparation.** Forming pinna prominences from
693 E14.5 embryos (both wild type and *mEC1*^{dup/dup}) were micro-dissected, washed with cold 1× PBS, and homogenized
694 using a Tissue-Tearor. Total RNA extraction followed the same protocol as for cell RNA extraction. RNA-seq
695 libraries were then prepared using the Illumina TruSeq RNA Library Prep Kit v2 (Illumina, catalog no. RS-122-

696 2001), adhering to the manufacturer's instructions. For each genotype, five independent biological replicates were
697 processed.

698 **Sample preparation, RNA isolation and single cell RNA-seq library preparation.** Single cell RNA-seq samples
699 were prepared as previously described²⁶. Briefly, micro-dissected forming pinna prominences from *Hmx1*^{wt/EGFP}
700 embryos were enzymatically dissociated using 0.5% trypsin/1× EDTA for 10 minutes at 37 °C (for E10.5 and E12.5
701 stages) and papain digestion mix for 7 minutes (for E14.5 stage). The treated tissues were then rinsed in ice-cold 1×
702 DMEM, filtered, and GFP⁺ cells were enriched using FACS (Sony, MA900). These collected cells were resuspended
703 and diluted in 1× DPBS (Cytiva, catalog no. SH30028.FS) to a concentration of 1×10⁶ cells per ml. Gene expression
704 libraries were prepared using GEXSCOPE Single Cell RNA Library Kits v.2 (Singleron, catalog no. SD-4180022).
705 The single-cell suspensions were loaded onto the GEXSCOPE microchip, which facilitates automated single cell
706 capture, cell lysis, cellular mRNA capture, and molecular labeling via the Singleron Matrix instrument. The barcoded
707 cDNA was amplified and utilized for constructing single cell NGS libraries. The quality and quantity of the resulting
708 libraries were assessed using Qubit 4.0 (Thermo Fisher Scientific) and Qseq100 (Bioptic). For gene expression
709 analysis, samples were sequenced on an Illumina NovaSeq platform to a depth of 500 million reads per channel.

710 **Whole-mount *in situ* hybridization (WISH).** The WISH procedure was carried out on whole-mount embryos
711 according to previously established protocols²⁶. Initially, mouse embryos were carefully dissected to remove
712 extraembryonic membranes and then immersed in cold 1× PBS. For fixation, embryos were submerged in 4%
713 paraformaldehyde in 1× PBS and gently rocked for 6 hours or overnight at 4°C in a sealed vial. Post-fixation,
714 embryos were thoroughly washed three times with PBST (1× PBS with 0.1% Tween-20), dehydrated through a
715 graded series of methanol-PBST solutions, and finally placed in 100% methanol for storage at -20°C until they were
716 processed further.

717 On the day of hybridization, the embryos were first rehydrated and then washed twice for 5 minutes each in
718 PBST. They were incubated for 1 hour in 6% hydrogen peroxide/PBST and subsequently washed again with PBST
719 at 4°C. Next, the embryos were treated with 10 µg/mL proteinase K (Roche, catalog no. 3115887001) in PBST for
720 a duration of 10 to 30 minutes, varying according to different embryonic stages, at room temperature. The proteinase
721 K reaction was halted by adding 2 mg/mL glycine in PBST. For pre-hybridization, embryos were incubated for 1
722 hour at 68°C in hybridization buffer, which comprised 50% deionized formamide, 5× SSC buffer, 1% SDS, 100
723 µg/mL yeast tRNA, and 50 µg/mL heparin. After this, digoxigenin-labeled probes (concentration ranging from 0.5
724 to 1 µg/mL) were added, and the embryos were incubated overnight at 68°C.

725 On the following day, embryos underwent a series of extensive washes. They were initially washed three times
726 for 30 minutes each in Wash 1 (50% regular formamide, 5× SSC buffer, 1% SDS). This was followed by a 10-minute
727 wash in a 1:1 mixture of Wash 1 and Wash 2 (0.5M NaCl, 10mM Tris HCl pH 7.5, 0.1% Tween-20), and then two
728 30-minute washes in Wash 2 containing 100 µg/mL RNaseA and 100 units/mL RNase T1 at 37°C. Further, embryos
729 were washed three times for 30 minutes each in Wash 3 (50% regular formamide, 2× SSC buffer) at 65°C, and then
730 three times for 10 minutes each in TBST (140mM NaCl, 2.5 mM NaCl, 25 mM Tris pH7.5, 0.1% Tween-20) at room
731 temperature. The embryos were then blocked for 2.5 hours at room temperature in block buffer (1% blocking reagent
732 in TBST) and incubated overnight at 4°C with anti-Digoxigenin-AP-conjugated antibody (dilution range: 1:1000 to
733 1:5000, Roche, catalog no. 11093274910) diluted in the same buffer.

734 On the third day, the embryos were subjected to five 10-minute washes, followed by five 60-minute washes in
735 TBST, and then left to wash overnight at 4°C. Lastly, the embryos were washed twice for 20 minutes each in NTMT
736 buffer (100mM NaCl, 100mM Tris pH 9.5, 50mM MgCl₂, 0.1% Tween-20) at room temperature. The color reaction
737 was developed using NBT/BCIP (Roche, catalog no. 11681451001) in NTMT buffer for 0.5 to 2 hours in the dark.

738 The reaction was stopped with three 10-minute washes in PBST, and the embryos were subsequently photographed

739 using a Carl Zeiss Axio Zoom V16 microscope, following the manufacturer's instructions.

740 **Frozen section *in situ* hybridizations.** Mouse embryos (wild type and *mEC1^{dup/dup}*) at E14.5 were dissected and

741 washed with cold 1× PBS before being fixed in 4% paraformaldehyde (PFA). The embryos underwent a dehydration

742 process using a series of sucrose/PBS solutions (10%, 20%, 30%). This was followed by an equal volume mixture

743 of OCT compound, with rotation for 30 minutes at room temperature. Embryos were then embedded in OCT on dry

744 ice and stored at -80°C until required. Cryostat sections of 20 µm thickness were prepared in a horizontal orientation

745 using a Leica CM1860. Before hybridization, frozen sections were thawed to room temperature and allowed to air

746 dry for at least one hour. They were then re-fixed using 4% PFA/PBS for 15 minutes, followed by three 5-minute

747 washes in 1× PBS. Acetylation was carried out in an acetic anhydride solution (1.35% (v/v) triethanolamine, 0.175%

748 (v/v) HCl, 0.25% (v/v) acetic anhydride) for 10 minutes at room temperature, and the sections were subsequently

749 washed three times for 5 minutes each in 1× PBS. Prehybridization was carried out at room temperature for 2 hours.

750 Digoxigenin (dig)-labeled probes were diluted to 1 µg/mL in hybridization buffer (50% deionized formamide, 5×

751 SSC buffer, 1% SDS, 100 µg/mL yeast tRNA, 50 µg/mL heparin), then heated to 80°C for 5 minutes. Approximately

752 400 µL of hybridization buffer was applied to each slide, covered with parafilm, and hybridized at 70°C for 16-18

753 hours. On the second day, the parafilm was removed by immersing slides in 5× SSC. This was followed by a series

754 of washes: 30 minutes in 5× SSC/50% formamide, 20 minutes in 2× SSC, and twice for 20 minutes each in 0.2×

755 SSC at 65°C. Subsequently, the sections were washed three times for 5 minutes each in MABT buffer at room

756 temperature. Blocking was performed for 1-2 hours in 2% Blocking reagent/MABT buffer. Anti-Dig-AP diluted at

757 1:2000 in blocking buffer was applied to the sections, which were then incubated overnight at 4°C. On day 3, the

758 sections were washed eight times for 5 minutes each in MABT, twice for 10 minutes each in NTMT buffer, followed

759 by application of BM purple (Roche, catalog no. 11442074001) in the dark for 2-6 hours, depending on the signal

760 development. The reaction was terminated by immersing the slides in MABT for two 10-minute washes, then post-
761 fixing in 4% PFA/PBS for 30 minutes, and washing three times for 5 minutes each in 1× PBS. The sections were
762 mounted with VectaMount AQ aqueous mounting medium (Vector Laboratories, catalog no. H-5501-60). Imaging
763 was performed using a LEICA Aperio Versa 8 microscope, and images were processed with ImageScope x64
764 software (version 12.4.6.5003).

765 **Micro-computed tomography (Micro-CT) analysis of ear structures.**

766 Mice were euthanized and whole heads imaged using a SkyScan 1276 micro-computed tomograph (Bruker,
767 Belgium). Scanning was performed at 18-micron resolution using the following parameters: 55 kV, 200 uA, 0.5 mm
768 Al filter; 0.4° rotation step over 360°, with 3-frame averaging. All raw scan data were reconstructed into multiplanar
769 slice data using NRecon V1.7.3.1 software (Bruker). Reconstructed data were then rendered in 3D with consistent
770 thresholding parameters using Drishti V3.0 Volume Exploration software (GitHub.com/nci/Drishti)⁷⁵ for gross visual
771 assessment of the craniofacial skeleton. Representative rendered images from animals of each genotype were
772 captured and processed using Photoshop (Adobe Creative Cloud).

773 **Computational analysis**

774 **RNA-seq data and GO enrichment analysis.** RNA sequencing reads were initially processed using fastp for
775 trimming of the paired-end data, with quality assessment performed via FASTQC (version 0.12.1). Subsequently,
776 the reads were aligned to the mouse reference genome (GRCm39) using the STAR aligner (version v2.7.11a).
777 Quantification of the alignment files was carried out using featureCounts (version 2.0.6), incorporating the gene
778 model parameter. Differential gene expression analysis was conducted utilizing the limma (version 3.56.2), Glimma
779 (version 2.10.0), and edgeR (version 3.42.4) packages. Significantly downregulated genes, defined by criteria of an
780 FDR ≤ 0.05 , log fold change ($\log FC$) < 0 , and log counts per million ($\log CPM$) ≥ 1 , were selected for Gene Ontology

781 (GO) enrichment analysis. This analysis was performed using the clusterProfiler package (version 4.8.3), with results
782 visualized via the treeplot function.

783 **ChIP-seq and CUT&RUN data analysis.** Publicly available ChIP-seq datasets for this study were obtained from
784 the GEO database, including datasets for d11hCNCC: GSE28874²⁶; P4hCNCC: GSE145327²⁵ and GSE70751²⁸;
785 mNCC: GSE89435¹⁷; Pinna: GSE211900²⁶. Sequencing reads were trimmed using fastp and aligned to either the
786 mouse (GRCm39) or human (GRCh38) reference genome using bowtie2 (version 2.4.0). Duplicate reads (marked
787 by Picard toolkits), non-unique, and low mapping quality reads were filtered out using sambamba. BigWig files,
788 with signals normalized using the RPGC method, were generated for visualization using deepTools2.0 (version
789 3.4.2). Peak calling against the INPUT sample was performed using Macs2 software (version 2.2.7.1). Additionally,
790 human embryonic craniofacial epigenetic data from stages CS13, CS14, CS15, and CS17 were accessed from
791 <https://cotney.research.uchc.edu/craniofacial/>²⁴.

792 CUT&RUN sequencing data were analyzed employing the CUT&RUNTools 2.0 pipeline, as previously
793 reported⁷⁷. For histone peak calling, the fragment size filter was deactivated, while for TFs, fragments larger than
794 120 bp were filtered out. Normalized bigwig files were generated using an alignment scale factor based on spike-in
795 reads from *E. coli* K12 strain MG1655. Two replicates for independent biological experiments were generated for
796 each antibody (IgG, H3K27ac, and TCF7L2).

797 **ATAC-seq data analysis.** ATAC-seq datasets used in this study were sourced from existing databases (d11hCNCC:
798 GSE108517²⁷; hESC and P4hCNCC: GSE145327²⁵; mNCC: GSE89436¹⁷; Pinna: GSE211899²⁶). The adapter
799 sequences were trimmed using the bbduk.sh script and the reads were subsequently aligned to the reference genome
800 using bowtie2. Low-quality reads were filtered out following the methodology described in the ChIP-seq data
801 analysis section. The alignmentSieve function with the -ATACshift parameter was employed to adjust for the

802 transposase binding pattern. For visualization purposes, bigwig files were generated utilizing the bamCoverage
803 function in deepTools 2.0 (version 3.5.2).

804 **Hi-C and PCHi-C data analysis.** For the capture Hi-C data of human cranial neural crest cells (hCNCCs), a genome
805 digest file for HindIII was created using hicup_digester. The HiCUP software (version 0.9.2) was then employed to
806 generate alignment files. To prepare files for the Chicago R package (version 1.30.0), scripts such as bam2chicago.sh
807 and makeDesignFiles.py from chicagoTools were utilized. The Chicago package produced washU_text format
808 results, showcasing interactions between two genomic positions. Interactions with a score ≥ 5 were considered high-
809 confidence and visualized as arcs using pygenometrack (version 3.9). Other PCHi-C datasets in this study (hESC:
810 GSE8682⁷⁸; Pinna: GSE211901²⁶) were downloaded in washU_txt format and similarly visualized with
811 pygenometrack without additional processing.

812 For the CS17 craniofacial Hi-C dataset (GSM5944420²⁴), the hic file was obtained for further analysis. We
813 firstly converted hic format to cool format using hicConverFormat function in HiCExplorer (version 3.7.2) with –
814 *resolutions* 100000, then hicFindTADs was applied for calling TAD regions with parameters: -
815 *thresholdComparisons* 0.05, *-delta* 0.01, *-correctForMultipleTesting* fdr.

816 **scRNA-seq analysis.** The scRNA-seq reads were processed using the CeleScope pipeline, details of which are
817 available at <https://github.com/singleron-RD/CeleScope>. This processing generated a 10x Genomics-like raw
818 feature-barcode matrix suitable for downstream filtering and data integration using Seurat (version 4.3.0). For cell
819 filtering, we assumed that both the log10-transformed gene counts and UMI counts per cell for each sample followed
820 a normal distribution. We calculated the mean \pm 1.96 times the standard deviation, defining the 95% confidence
821 interval, to determine the lower and upper thresholds. These thresholds were then converted back to the original
822 scale (as the power of 10 of the log values) to establish criteria for excluding low-quality cells. Furthermore, cells
823 exhibiting a mitochondrial gene expression ratio exceeding 5% were also categorized as low quality.

824 Data integration was accomplished using the CCA2-based pipeline of Seurat package. The
825 SelectIntegrationFeatures function was utilized to identify variable features across datasets for integration.
826 Subsequently, the FindIntegrationAnchors function was employed to identify anchor pairs between datasets,
827 followed by the IntegrateData function to create an integrated assay, which included the newly integrated expression
828 profiles. Based on the results of integration, we performed PCA dimensionality reduction using RunPCA on the
829 variable features employed for integration. This was followed by UMAP dimensionality reduction using RunUMAP
830 with parameters *-dims 1:20, -n.neighbors 50*. For unsupervised clustering, we executed the FindNeighbors function
831 using default parameters, and FindClusters with *-resolution 0.4*.

832 **PAGA developmental trajectory analysis.** The integrated expression profiles were imported into SCANPY
833 (version 1.9.3) for the construction of the fibroblast differentiation trajectory employing the Partition-based Graph
834 Abstraction (PAGA) algorithm. For this analysis, a total of 4,994 cells, equally proportioned from each sample and
835 cell type, were subsetted for trajectory construction. The `scanpy.tl.paga` function was utilized to construct a PAGA
836 graph, which facilitated the visualization of cell population structures. This visualization was achieved using
837 `sc.tl.draw_graph`, producing a force-directed graph drawing. The root cell for the trajectory was designated as a cell
838 from the Mitotic CNCC-derived mesenchymal cell population. Diffusion pseudotime was calculated using
839 `scanpy.tl.diffmap` and `scanpy.tl.dpt` functions. Additionally, the `cellrank.kernels.PseudotimeKernel` function from the
840 CellRank package (version 2.0.2) was employed to construct the `cellrank` pseudotime kernel. This kernel was crucial
841 for computing the cell-cell transition matrix. The pseudotime results were ultimately visualized as embeddings on
842 the force-directed graph, providing insights into the developmental trajectory of fibroblast differentiation.

843 **Motif analysis.** Motif prediction on hEC1 sequence was performed using FIMO software in the MEME Suite
844 (version 5.5.3). The motifs used in the prediction process were downloaded from HOCOMOCO database (v12)
845 containing a collection of 1443 motifs, and the threshold *P*-value of 1E-4 was used to identify high-affinity binding

846 sites. After the preliminary results, we further used the single cell expression datasets from human embryos
847 (GSE157329) to filter TFs that are not expressed (TFs must be expressed in cells expressing the *HMX1* gene in no
848 less than 10% of the cells) with the *HMX1* gene. Additionally, through the ALX1/4 prediction *P*-value is larger than
849 1E-4, we also present it in the Figure 3 considering the very close distance to the very high MEIS1/PBX1 binding
850 site and potentially influence. Finally, we further confirm the binding pattern of HD, HMG-box, and Coordinator in
851 the D3-D4 region using sequence motif location tool (MoLoTool).

852 **EChO analysis.** The Enhanced Chromatin Occupancy (EChO) analysis was conducted following previously
853 established protocols^{31,63}. The process began with the generation of two bed files using bedtools: one representing
854 the region file (TCF7L2 occupied peaks on hEC1 extended by ± 500 bp) and the other being the fragment file.
855 Detailed bedtools procedures for EChO can be found at <https://github.com/FredHutch/EChO>. Utilizing the region
856 file, the foci mode of EChO was implemented to identify single base-pair foci as the centers of matrices. Additionally,
857 the matrix mode was executed over a 400 bp window for each focus. This approach generated a matrix of base pair-
858 resolution EChO fragment size values, facilitating subsequent visualization. For the analysis of high and low motif
859 scores, TCF7L2 matrix profiles (including MA0523.1 and MA0523.2,) were retrieved from the JASPAR database.
860 These profiles were scanned across a 40 bp window surrounding each focus. Motifs with scores exceeding 80% were
861 categorized as high-scoring, while those above 70% were deemed low-scoring motifs.
862
863

864 **Acknowledgments**

865 We would like to thank the patients and their families for their participation in the study. In addition,
866 we would like to thank Weiqiang Li, Peng Xiang (from Sun Yat-sen University) and Sahin Naqvi
867 (from Stanford University) for helping in neural crest cell culture. We also would like to thank
868 Yanxiao Zhang (from Westlake University) for advice on our LacZ experiments. This study was
869 supported by grants from the National Natural Science Foundation of China (82202047 to X.X.,
870 82171844 and 81970898 to Y-B.Z., and 81671933 to J.H), China Postdoctoral Science Foundation
871 (2022M722228 to X.X.), and the Special Research Fund for Plastic Surgery Hospital, Chinese
872 Academy of Medical Sciences and Peking Union Medical College (YS202041 to Q.C.), the Key
873 Research and Development Program of Guangzhou (202206060002 to X.F.), the Guangdong
874 Provincial Pearl River Talents Program (2021QN02Y747 to X.F.) and a Stowers Family
875 Endowment to T.C.C. The funders had no role in study design, data collection and analysis, decision
876 to publish, or preparation of the manuscript.

877

878 **Conflict of interest statement**

879 The authors have declared that no conflict of interest exists.

880

881 **Author contributions**

882 Y-B.Z., X.X., and H.L. designed and supervised the study. Q.C., Q.L., J.H., B.W., Q.Z., and Y-B.Z.
883 recruited case samples. X.X., X.F., Q.H., Z.M., H.Z., Z.L., J.Z., J.L., and Q.C. planned and
884 conducted laboratory experiments. X.X, X.H., B.X., W.X., R.L., Z.M., and T.C.C. analyzed data.

885 X.X., Y-B.Z., J.Z., X.F., T.C.C, S.E.A, and H.L. drafted and revised the manuscript. All authors
886 have reviewed and contributed to the manuscript.

887

888 **Data availability**

889 All raw sequencing data and processed data in this study are currently being uploaded and will be
890 made publicly accessible via the Gene Expression Omnibus (GEO) following the publication of the
891 article. In addition, we used following public sequencing datasets: ChIP-seq datasets: GSE28874
892 (d11hCNCC), GSE145327 (P4hCNCC), GSE70751(P4hCNCC), GSE89435 (mCNCC),
893 GSE211900 (Pinna). ATAC-seq datasets: GSE108517 (d11hCNCC), GSE145327 (hESC and
894 P4hCNCC), GSE89436 (mCNCC), GSE211899 (Pinna). HiC dataset: GSM5944420 (CS17 head
895 tissue). scRNA-seq dataset: GSE157329 (single-cell transcriptomes of 4- to 6-week human
896 embryos). Additionally, human embryonic craniofacial epigenetic data from stages CS13, CS14,
897 CS15, and CS17 were accessed from <https://cotney.research.uchc.edu/craniofacial/>.

898

899 **Code availability**

900 Computational procedures were conducted utilizing Python and R software, harnessing publicly
901 available packages as delineated in the Methods and Reporting Summary sections. The analyses of
902 data presented in this study did not rely on any unpublished custom computer code, mathematical
903 algorithms, or software.

904

905 **References**

906 1 Atchley, W. R. & Hall, B. K. A model for development and evolution of complex
907 morphological structures. *Biol Rev Camb Philos Soc* **66**, 101-157 (1991).
908 <https://doi.org/10.1111/j.1469-185x.1991.tb01138.x>

909 2 Fuchs, J. C. & Tucker, A. S. Development and Integration of the Ear. *Curr Top Dev Biol* **115**,
910 213-232 (2015). <https://doi.org/10.1016/bs.ctdb.2015.07.007>

911 3 Anthwal, N. & Thompson, H. The development of the mammalian outer and middle ear. *J
912 Anat* **228**, 217-232 (2016). <https://doi.org/10.1111/joa.12344>

913 4 Alasti, F. *et al.* A mutation in HOXA2 is responsible for autosomal-recessive microtia in an
914 Iranian family. *Am J Hum Genet* **82**, 982-991 (2008).
915 <https://doi.org/10.1016/j.ajhg.2008.02.015>

916 5 Zhang, Y., Fons, J. M., Hajihosseini, M. K., Zhang, T. & Tucker, A. S. An Essential
917 Requirement for Fgf10 in Pinna Extension Sheds Light on Auricle Defects in LADD
918 Syndrome. *Front Cell Dev Biol* **8**, 609643 (2020). <https://doi.org/10.3389/fcell.2020.609643>

919 6 Lausch, E. *et al.* TBX15 mutations cause craniofacial dysmorphism, hypoplasia of scapula and
920 pelvis, and short stature in Cousin syndrome. *Am J Hum Genet* **83**, 649-655 (2008).
921 <https://doi.org/10.1016/j.ajhg.2008.10.011>

922 7 Minoux, M. *et al.* Mouse Hoxa2 mutations provide a model for microtia and auricle
923 duplication. *Development* **140**, 4386-4397 (2013). <https://doi.org/10.1242/dev.098046>

924 8 Quina, L. A. *et al.* Deletion of a conserved regulatory element required for Hmx1 expression
925 in craniofacial mesenchyme in the dumbo rat: a newly identified cause of congenital ear
926 malformation. *Dis Model Mech* **5**, 812-822 (2012). <https://doi.org/10.1242/dmm.009910>

927 9 Koch, C. T., Bruggmann, R., Tetens, J. & Drögemüller, C. A non-coding genomic duplication
928 at the HMX1 locus is associated with crop ears in highland cattle. *PLoS ONE* **8**, e77841
929 (2013).

930 10 Si, N. *et al.* Duplications involving the long range HMX1 enhancer are associated with human
931 isolated bilateral concha-type microtia. *J Transl Med* **18**, 244 (2020).
932 <https://doi.org/10.1186/s12967-020-02409-6>

933 11 Rosin, J. M. *et al.* A distal 594 bp ECR specifies Hmx1 expression in pinna and lateral facial
934 morphogenesis and is regulated by the Hox-Pbx-Meis complex. *Development* **143**, 2582-2592
935 (2016). <https://doi.org/10.1242/dev.133736>

936 12 Will, A. J. *et al.* Composition and dosage of a multipartite enhancer cluster control
937 developmental expression of Ihh (Indian hedgehog). *Nat Genet* **49**, 1539-1545 (2017).
938 <https://doi.org/10.1038/ng.3939>

939 13 Jindal, G. A. & Farley, E. K. Enhancer grammar in development, evolution, and disease:
940 dependencies and interplay. *Dev Cell* **56**, 575-587 (2021).
941 <https://doi.org/10.1016/j.devcel.2021.02.016>

942 14 Xu, X. *et al.* Novel risk factors for craniofacial microsomia and assessment of their utility in
943 clinic diagnosis. *Hum. Mol. Genet.* (2021). <https://doi.org/10.1093/hmg/ddab055>

944 15 Mao, K. *et al.* FOXI3 pathogenic variants cause one form of craniofacial microsomia. *Nat
945 Commun* **14**, 2026 (2023). <https://doi.org/10.1038/s41467-023-37703-6>

946 16 Zhang, Y. B. *et al.* Genome-wide association study identifies multiple susceptibility loci for
947 craniofacial microsomia. *Nat Commun* **7**, 10605 (2016).
<https://doi.org/10.1038/ncomms10605>

949 17 Minoux, M. *et al.* Gene bivalency at Polycomb domains regulates cranial neural crest
950 positional identity. *Science* **355** (2017). <https://doi.org/10.1126/science.aal2913>

951 18 Selleri, L. & Rijli, F. M. Shaping faces: genetic and epigenetic control of craniofacial
952 morphogenesis. *Nat Rev Genet* **24**, 610-626 (2023). <https://doi.org/10.1038/s41576-023-00594-w>

954 19 Minoux, M. & Rijli, F. M. Molecular mechanisms of cranial neural crest cell migration and
955 patterning in craniofacial development. *Development* **137**, 2605-2621 (2010).
<https://doi.org/10.1242/dev.040048>

957 20 Depew, M. J., Lufkin, T. & Rubenstein, J. L. Specification of jaw subdivisions by Dlx genes.
958 *Science* **298**, 381-385 (2002). <https://doi.org/10.1126/science.1075703>

959 21 Yuan, Y. *et al.* Spatiotemporal cellular movement and fate decisions during first pharyngeal
960 arch morphogenesis. *Sci Adv* **6** (2020). <https://doi.org/10.1126/sciadv.abb0119>

961 22 Wilderman, A. *et al.* A distant global control region is essential for normal expression of
962 anterior HOXA genes during mouse and human craniofacial development. *Nat Commun* **15**,
963 136 (2024). <https://doi.org/10.1038/s41467-023-44506-2>

964 23 Xu, Y. *et al.* A single-cell transcriptome atlas profiles early organogenesis in human embryos.
965 *Nat Cell Biol* **25**, 604-615 (2023). <https://doi.org/10.1038/s41556-023-01108-w>

966 24 Wilderman, A., VanOudenhove, J., Kron, J., Noonan, J. P. & Cotney, J. High-Resolution
967 Epigenomic Atlas of Human Embryonic Craniofacial Development. *Cell Rep* **23**, 1581-1597
968 (2018). <https://doi.org/10.1016/j.celrep.2018.03.129>

969 25 Long, H. K. *et al.* Loss of Extreme Long-Range Enhancers in Human Neural Crest Drives a
970 Craniofacial Disorder. *Cell Stem Cell* **27**, 765-783 e714 (2020).
<https://doi.org/10.1016/j.stem.2020.09.001>

972 26 Kessler, S. *et al.* A multiple super-enhancer region establishes inter-TAD interactions and
973 controls Hoxa function in cranial neural crest. *Nat Commun* **14**, 3242 (2023).
<https://doi.org/10.1038/s41467-023-38953-0>

975 27 Laugsch, M. *et al.* Modeling the Pathological Long-Range Regulatory Effects of Human
976 Structural Variation with Patient-Specific hiPSCs. *Cell Stem Cell* **24**, 736-752 e712 (2019).
<https://doi.org/10.1016/j.stem.2019.03.004>

978 28 Prescott, S. L. *et al.* Enhancer divergence and cis-regulatory evolution in the human and
979 chimp neural crest. *Cell* **163**, 68-83 (2015). <https://doi.org/10.1016/j.cell.2015.08.036>

980 29 Chen, L. F. *et al.* Structural elements promote architectural stripe formation and facilitate
981 ultra-long-range gene regulation at a human disease locus. *Mol Cell* (2023).
<https://doi.org/10.1016/j.molcel.2023.03.009>

983 30 Kim, S. *et al.* DNA-guided transcription factor cooperativity shapes face and limb
984 mesenchyme. *Cell* **187**, 692-711 e626 (2024). <https://doi.org/10.1016/j.cell.2023.12.032>

985 31 Meers, M. P., Janssens, D. H. & Henikoff, S. Pioneer Factor-Nucleosome Binding Events
986 during Differentiation Are Motif Encoded. *Mol Cell* **75**, 562-575 e565 (2019).
<https://doi.org/10.1016/j.molcel.2019.05.025>

988 32 Munroe, R. J. *et al.* Mouse H6 Homeobox 1 (Hmx1) mutations cause cranial abnormalities
989 and reduced body mass. *BMC Dev Biol* **9**, 27 (2009). <https://doi.org/10.1186/1471-213X-9-27>

990 33 Allen, R. S., Biswas, S. K. & Seifert, A. W. Neural crest cells give rise to non-myogenic
991 mesenchymal tissue in the adult murid ear pinna. *bioRxiv* (2023).
992 <https://doi.org/10.1101/2023.08.06.552195>

993 34 Muhl, L. *et al.* Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast
994 and mural cell identification and discrimination. *Nat Commun* **11**, 3953 (2020).
995 <https://doi.org/10.1038/s41467-020-17740-1>

996 35 Vallecillo-Garcia, P. *et al.* Odd skipped-related 1 identifies a population of embryonic fibro-
997 adipogenic progenitors regulating myogenesis during limb development. *Nat Commun* **8**, 1218
998 (2017). <https://doi.org/10.1038/s41467-017-01120-3>

999 36 Contreras, O. & Harvey, R. P. Single-cell transcriptome dynamics of the autotaxin-
1000 lysophosphatidic acid axis during muscle regeneration reveal proliferative effects in
1001 mesenchymal fibro-adipogenic progenitors. *Front Cell Dev Biol* **11**, 1017660 (2023).
1002 <https://doi.org/10.3389/fcell.2023.1017660>

1003 37 Phan, Q. M. *et al.* Lineage Commitment of Dermal Fibroblast Progenitors is Mediated by
1004 Chromatin De-repression. *bioRxiv* (2023). <https://doi.org/10.1101/2023.03.07.531478>

1005 38 Han, X. *et al.* Runx2-Twist1 interaction coordinates cranial neural crest guidance of soft palate
1006 myogenesis. *Elife* **10** (2021). <https://doi.org/10.7554/elife.62387>

1007 39 Kemmler, C. L. *et al.* Conserved enhancers control notochord expression of vertebrate
1008 Brachyury. *Nat Commun* **14**, 6594 (2023). <https://doi.org/10.1038/s41467-023-42151-3>

1009 40 Kvon, E. Z., Waymack, R., Gad, M. & Wunderlich, Z. Enhancer redundancy in development
1010 and disease. *Nat Rev Genet* **22**, 324-336 (2021). <https://doi.org/10.1038/s41576-020-00311-x>

1011 41 Frankel, N. *et al.* Phenotypic robustness conferred by apparently redundant transcriptional
1012 enhancers. *Nature* **466**, 490-493 (2010). <https://doi.org/10.1038/nature09158>

1013 42 Osterwalder, M. *et al.* Enhancer redundancy provides phenotypic robustness in mammalian
1014 development. *Nature* **554**, 239-243 (2018). <https://doi.org/10.1038/nature25461>

1015 43 Wang, X. & Goldstein, D. B. Enhancer Domains Predict Gene Pathogenicity and Inform Gene
1016 Discovery in Complex Disease. *Am J Hum Genet* **106**, 215-233 (2020).
1017 <https://doi.org/10.1016/j.ajhg.2020.01.012>

1018 44 Waymack, R., Fletcher, A., Enciso, G. & Wunderlich, Z. Shadow enhancers can suppress input
1019 transcription factor noise through distinct regulatory logic. *Elife* **9** (2020).
1020 <https://doi.org/10.7554/elife.59351>

1021 45 Thomas, H. F. *et al.* Temporal dissection of an enhancer cluster reveals distinct temporal and
1022 functional contributions of individual elements. *Mol Cell* **81**, 969-982 e913 (2021).
1023 <https://doi.org/10.1016/j.molcel.2020.12.047>

1024 46 Perry, M. W., Boettiger, A. N. & Levine, M. Multiple enhancers ensure precision of gap gene-
1025 expression patterns in the Drosophila embryo. *Proc Natl Acad Sci U S A* **108**, 13570-13575
1026 (2011). <https://doi.org/10.1073/pnas.1109873108>

1027 47 Choi, J. *et al.* Evidence for additive and synergistic action of mammalian enhancers during
1028 cell fate determination. *Elife* **10** (2021). <https://doi.org/10.7554/elife.65381>

1029 48 Carleton, J. B., Berrett, K. C. & Gertz, J. Multiplex Enhancer Interference Reveals
1030 Collaborative Control of Gene Regulation by Estrogen Receptor alpha-Bound Enhancers. *Cell
1031 Syst* **5**, 333-344 e335 (2017). <https://doi.org/10.1016/j.cels.2017.08.011>

1032 49 Blayney, J. W. *et al.* Super-enhancers include classical enhancers and facilitators to fully
1033 activate gene expression. *Cell* **186**, 5826-5839 e5818 (2023).
<https://doi.org/10.1016/j.cell.2023.11.030>

1034 50 Vockley, C. M. *et al.* Direct GR Binding Sites Potentiate Clusters of TF Binding across the
1035 Human Genome. *Cell* **166**, 1269-1281 e1219 (2016).
<https://doi.org/10.1016/j.cell.2016.07.049>

1036 51 Kim, S. & Wysocka, J. Deciphering the multi-scale, quantitative cis-regulatory code. *Mol Cell*
1037 **83**, 373-392 (2023). <https://doi.org/10.1016/j.molcel.2022.12.032>

1038 52 Rajderkar, S. S. *et al.* Dynamic enhancer landscapes in human craniofacial development. *Nat*
1039 *Commun* **15**, 2030 (2024). <https://doi.org/10.1038/s41467-024-46396-4>

1040 53 Zaugg, J. B. *et al.* Current challenges in understanding the role of enhancers in disease. *Nat*
1041 *Struct Mol Biol* **29**, 1148-1158 (2022). <https://doi.org/10.1038/s41594-022-00896-3>

1042 54 Spitz, F. & Furlong, E. E. Transcription factors: from enhancer binding to developmental
1043 control. *Nat Rev Genet* **13**, 613-626 (2012). <https://doi.org/10.1038/nrg3207>

1044 55 Taskiran, II *et al.* Cell-type-directed design of synthetic enhancers. *Nature* (2023).
<https://doi.org/10.1038/s41586-023-06936-2>

1045 56 Wong, E. S. *et al.* Deep conservation of the enhancer regulatory code in animals. *Science* **370**
1046 (2020). <https://doi.org/10.1126/science.aax8137>

1047 57 Marinic, M., Aktas, T., Ruf, S. & Spitz, F. An integrated holo-enhancer unit defines tissue and
1048 gene specificity of the Fgf8 regulatory landscape. *Dev Cell* **24**, 530-542 (2013).
<https://doi.org/10.1016/j.devcel.2013.01.025>

1049 58 Montavon, T. *et al.* A regulatory archipelago controls Hox genes transcription in digits. *Cell*
1050 **147**, 1132-1145 (2011). <https://doi.org/10.1016/j.cell.2011.10.023>

1051 59 Dermitzakis, E. T. *et al.* Numerous potentially functional but non-genic conserved sequences
1052 on human chromosome 21. *Nature* **420**, 578-582 (2002). <https://doi.org/10.1038/nature01251>

1053 60 Dermitzakis, E. T. *et al.* Evolutionary discrimination of mammalian conserved non-genic
1054 sequences (CNGs). *Science* **302**, 1033-1035 (2003). <https://doi.org/10.1126/science.1087047>

1055 61 Attanasio, C. *et al.* Fine tuning of craniofacial morphology by distant-acting enhancers.
1056 *Science* **342**, 1241006 (2013). <https://doi.org/10.1126/science.1241006>

1057 62 Amin, S. *et al.* Hoxa2 selectively enhances Meis binding to change a branchial arch ground
1058 state. *Dev Cell* **32**, 265-277 (2015). <https://doi.org/10.1016/j.devcel.2014.12.024>

1059 63 Azambuja, A. P. & Simoes-Costa, M. The connectome of neural crest enhancers reveals
1060 regulatory features of signaling systems. *Dev Cell* **56**, 1268-1282 e1266 (2021).
<https://doi.org/10.1016/j.devcel.2021.03.024>

1061 64 Franke, M. *et al.* Formation of new chromatin domains determines pathogenicity of genomic
1062 duplications. *Nature* **538**, 265-269 (2016). <https://doi.org/10.1038/nature19800>

1063 65 Zhang, X. *et al.* Identification of focally amplified lineage-specific super-enhancers in human
1064 epithelial cancers. *Nat Genet* **48**, 176-182 (2016). <https://doi.org/10.1038/ng.3470>

1065 66 Ma, S. *et al.* Developmentally regulated expression of integrin alpha-6 distinguishes neural
1066 crest derivatives in the skin. *Front Cell Dev Biol* **11**, 1140554 (2023).
<https://doi.org/10.3389/fcell.2023.1140554>

1067 67 Quiat, D. *et al.* An ancient founder mutation located between ROBO1 and ROBO2 is
1068 responsible for increased microtia risk in Amerindigenous populations. *Proc Natl Acad Sci U*
1069 *SA* **119**, e2203928119 (2022). <https://doi.org/10.1073/pnas.2203928119>

1076 68 Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform.
1077 *Bioinformatics* **25**, 1754-1760 (2009). <https://doi.org/btp324> [pii]
1078 10.1093/bioinformatics/btp324

1079 69 Abecasis, G. R., Cherny, S. S., Cookson, W. O. & Cardon, L. R. Merlin--rapid analysis of
1080 dense genetic maps using sparse gene flow trees. *Nat. Genet.* **30**, 97-101 (2002).
1081 <https://doi.org/10.1038/ng786>

1082 70 Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
1083 datasets. *Gigascience* **4**, 7 (2015). <https://doi.org/10.1186/s13742-015-0047-8>

1084 71 Klambauer, G. *et al.* cn.MOPS: mixture of Poissons for discovering copy number variations in
1085 next-generation sequencing data with a low false discovery rate. *Nucleic Acids Res.* **40**, e69
1086 (2012). <https://doi.org/10.1093/nar/gks003>

1087 72 Rao, S. S. *et al.* A 3D map of the human genome at kilobase resolution reveals principles of
1088 chromatin looping. *Cell* **159**, 1665-1680 (2014). <https://doi.org/10.1016/j.cell.2014.11.021>

1089 73 Mifsud, B. *et al.* Mapping long-range promoter contacts in human cells with high-resolution
1090 capture Hi-C. *Nat Genet* **47**, 598-606 (2015). <https://doi.org/10.1038/ng.3286>

1091 74 Kvon, E. Z. *et al.* Progressive Loss of Function in a Limb Enhancer during Snake Evolution.
1092 *Cell* **167**, 633-642 e611 (2016). <https://doi.org/10.1016/j.cell.2016.09.028>

1093 75 Stock, S. R. & Limaye, A. in *Developments in X-Ray Tomography VIII* (2012).

1094 76 Rada-Iglesias, A. *et al.* Epigenomic annotation of enhancers predicts transcriptional regulators
1095 of human neural crest. *Cell Stem Cell* **11**, 633-648 (2012).
<https://doi.org/10.1016/j.stem.2012.07.006>

1097 77 Yu, F., Sankaran, V. G. & Yuan, G. C. CUT&RUNTools 2.0: a pipeline for single-cell and
1098 bulk-level CUT&RUN and CUT&Tag data analysis. *Bioinformatics* **38**, 252-254 (2021).
<https://doi.org/10.1093/bioinformatics/btab507>

1100 78 Freire-Pritchett, P. *et al.* Global reorganisation of cis-regulatory units upon lineage
1101 commitment of human embryonic stem cells. *Elife* **6** (2017).
<https://doi.org/10.7554/elife.21926>

1103 79 Cox, T. C., Camci, E. D., Vora, S., Luquetti, D. V. & Turner, E. E. The genetics of auricular
1104 development and malformation: new findings in model systems driving future directions for
1105 microtia research. *Eur J Med Genet* **57**, 394-401 (2014).
<https://doi.org/10.1016/j.ejmg.2014.05.003>

1107 80 Posey, K. L., Country, F. & Hecht, J. T. Cartilage oligomeric matrix protein: COMPopathies
1108 and beyond. *Matrix Biol* **71-72**, 161-173 (2018). <https://doi.org/10.1016/j.matbio.2018.02.023>

1109 81 Melo, U. S. *et al.* Enhancer hijacking at the ARHGAP36 locus is associated with connective
1110 tissue to bone transformation. *Nat Commun* **14**, 2034 (2023). <https://doi.org/10.1038/s41467-023-37585-8>

1112

1113

1114 **Figure Legend**

1115 **Fig. 1 | Duplication of non-coding region downstream of *HMX1* as a pathogenic factor in**
1116 **Bilateral Constricted Ears (BCEs).**

1117 **a**, Pedigrees of seven families with BCEs. Each individual's pedigree identity is indicated below
1118 their symbol. Gold arrows denote the proband in each family. Squares represent males and circles
1119 females; black shading indicates affected individuals, while gray shading denotes unknown
1120 phenotype. Triangles, stars, and rectangles symbolize chip analysis, target-capture sequencing, and
1121 whole-genome sequencing, respectively.

1122 **b**, Representative images of affected ears from the proband patients and their families, in each
1123 pedigree.

1124 **c**, Copy number duplication in each family, located in the intergenic region downstream of the
1125 *HMX1* gene, within the same TAD. The top panel displays Hi-C data from human embryo CS17
1126 head tissue²², with the black triangle marking the TAD region (TAD including BCE locus was
1127 marked red). In the middle panel, the H3K36me3 signal, a marker frequently observed at TAD
1128 boundaries, is depicted across this region. The lower panel specifies the duplication regions for each
1129 family, highlighting the minimum overlapping genomic area (chr4: 8691119-8728565, termed BCE
1130 locus) and the genes located within the TAD. Two protein-coding genes including *CPZ* and *HMX1*
1131 are highlighted.

1132

1133 **Fig. 2 | Identification and characterization of candidate enhancers at the BCE locus.**

1134 **a**, Epigenomic profiling pinpoints enhancer elements at the BCE locus. Integrated epigenomic
1135 analysis of the BCE locus, combining *in vivo* data from human embryo craniofacial tissue at stages
1136 CS13-CS17 (including ear progenitor regions, upper part)²⁴ with *in vitro* data from hESCs-derived
1137 human Cranial Neural Crest Cells (hCNCCs, lower part)²⁸. CNV region shared across seven
1138 pedigrees is outlined by the golden rectangle. The chromatin state is represented through color
1139 coding, as defined on the Cotney lab craniofacial epigenome website
1140 (<https://cotney.research.uchc.edu/craniofacial/>). The epigenetic marks H3K4me3, H3K27me3,
1141 H3K27ac, and the presence of the transcriptional coactivator p300, in addition to H3K4me1 and
1142 CTCF signals in hCNCCs, are displayed. Candidate enhancers EC1, EC2, and EC3 are identified
1143 based on both datasets and are indicated by black rectangles.

1144 **b**, Differential chromatin interactions link CE enhancers to *HMX1* promoter. Promoter Capture Hi-
1145 C (PC-HiC) analysis demonstrates the differential physical interactions between the CE locus and
1146 the *HMX1* promoter in hESCs compared to hCNCCs. The line color denotes the interaction strength,
1147 and the TAD boundary identified in Fig. 1 is depicted. ATAC-seq data and PC-HiC data for hESCs
1148 are sourced from GSE145327²⁵ and GSE86821⁷⁸, respectively. Panels a and b share the same
1149 physical genomic coordinates.

1150

1151 **Fig. 3 | Spatiotemporal regulation of *HMX1* expression by multipartite enhancers**

1152 **a**, Epigenetic profiling at the BCE locus in early (D11) and late hCNCCs (P4).

1153 **b**, Schematic of hESCs differentiation to PA-like hCNCCs: The process involves transitioning H9
1154 cell line hESCs to early hCNCCs using NCC induction (NCCI) medium, followed by BMP2/ChIR
1155 treatment to reach late hCNCCs stage, and finally achieving PA-like hCNCCs with retinoic acid
1156 (RA) introduction.

1157 **c**, *HMX1* expression analysis across four cell states, presented as mean \pm S.E.M. (n = 6).
1158 **d-e**, Luciferase assays evaluating candidate enhancers at the BCE locus in hESC (**d**), and PA-like
1159 hCNCC (**e**), including SV40 enhancer (positive control) and empty vector (negative control).
1160 Results from three independent experiments, each with four technical replicates (n = 12), are shown.
1161 **f**, CRISPR/Cas9 strategy to delete two active enhancers (hEC1 and hEC2, ~9 kb), and gene
1162 expression comparison across four cell states in WT and knockout cell lines (n = 3).
1163 **g**, Spatiotemporal *Hmx1* expression from E9.5 to E14.5: Left panel – WISH image and fluorescent
1164 images of *Hmx1*-P2A-EGFP transgenic mouse reporter line (**Extended Data Fig. 4j**); Right panel
1165 - *Hmx1* expression predominantly in the PA2 zone and pinna region, and the spatial location of
1166 *Hmx1* expression at E11.5 is manually divided into α (proximal), β (distal), γ (caudal to PA2)
1167 positions according to corresponding PA2 zones. cm, craniofacial mesenchyme; bp, basal pinna; lp,
1168 lower part of pinna; dp, distal pinna; pmp, the proximal region of the mandibular prominence.
1169 **h-m**, LacZ assays during pinna development for various enhancers (hEC1, hEC2.1, hEC2,
1170 hEC1+hEC2, hEC3, and hEC1+hEC2+hEC3). The orange number in the bottom right corner of
1171 each embryo indicates the count of positive LacZ staining embryos, with the black number denoting
1172 the total count of transgenic embryos examined (**Extended Data Fig. 4d-i**). The black star on the
1173 E9.5 embryo of hEC2.1 marks weak activity at the basal of PA2. Two clearly visible staining
1174 positions in the upper distal part of pinna and lower pinna part adjacent to the proximal mandibular
1175 region on hEC1+hEC2+hEC3 E14.5 embryo compared with other enhancer constructs were marked
1176 as red triangle.
1177

1178 **Fig. 4 | The grammar of the hEC1 enhancer is shaped by multifactorial transcription factors**
1179 **a**, Motif analysis on the hEC1 sequence using FIMO is shown. The color intensity represents the
1180 affinity of the predicted TFBSSs, with the previously identified core 32bp marked¹¹. Five clusters of
1181 motifs, including D1 (162 bp), D2 (141 bp), D3 (182 bp), D4 (178 bp), and D5 (182 bp), are
1182 sequentially deleted.
1183 **b**, hEC1 activity is evaluated using *in vitro* (luciferase assay in PA-like hCNCCs line, upper panel)
1184 and *in vivo* (LacZ staining, bottom panel) strategies, across three independent experiments with two
1185 technical replicates each (n = 6). The red number in the bottom right corner of the embryo represents
1186 the number of positive LacZ staining embryos, see also **Extended Data Fig. 5a**.
1187 **c**, Dissection of motif structure across a core region linking D3 with D4. Two 76 bp duplication
1188 regions previously reported in sheep and cow are shown in the top panel, respectively. The middle
1189 panel displays DNA alignment across human, mouse, sheep and cow using T-coffee software. Four
1190 TFBSSs were highlighted and the underlie marked the core motif sequence. The bottom panel shows
1191 motifs from HOCOMOCO V12 database. Two deletions including Δ D3-1 and Δ D4-1 used in
1192 **Fig. 5g** are shown.
1193 **d**, CUT&RUN assay of H3K27ac, TWIST1 and TCF7L2 across the BCE locus.
1194 **e**, Local minimal DNA protection by TF-DNA binding (EChO) reveals multiple TCF7L2-binding
1195 sites across the hEC1 sequence. Purple and blue lines represent foci positions associated with high-
1196 and low-score TCF7L2 motifs, respectively.
1197 **f**, An EMSA assay reveals the binding of human MEIS1 protein to the predicted motif binding site
1198 in c.
1199 **g**, A luciferase assay demonstrates that removal of Δ D4-1 containing HMG-box and Coordinator
1200 dramatically diminish the activity of hEC1 in hCNCCs (n = 4).

1201 **h**, A complex heatmap shows TFs expression across four craniofacial regional zones: frontonasal
1202 process (FNP), maxilla (Mx), mandible (Md), and PA2 at E10.5 and E11.5¹⁷. Gene expression is
1203 scaled and clustering is performed.

1204 **i**, WISH images of four critical TFs including *Meis1*, *Tcf7l2*, *Twist1* and *Tcf4*. Images are from
1205 Emage database (<https://www.emouseatlas.org/emage/home.php>).

1206

1207 **Fig. 5 | mEC1 Knock-in in mouse recapitulates human constricted ear phenotypes, and mEC1-
1208 dependent *Hmx1* expression in mCNCCs is important for ear development.**

1209 **a**, A CRISPR/Cas9 genome editing strategy is used to insert mEC1.

1210 **b**, Sanger sequencing of PCR product in *mEC1^{dup/dup}* using two primers flanking mEC1.

1211 **c**, The expression pattern of mEC1 at E14.5, as shown using enSERT technology, is presented (n =
1212 7; see also **Extended Data Fig. 6b**).

1213 **d**, Illustration of mouse pinna structure adapted from *Cox et al.*,⁷⁹ highlighting components such as
1214 the tragus, anti-tragus, scapha, helix, and anti-helix.

1215 **e**, Side view comparison of wild type and homozygous mEC1 knock-in mouse models, with the red
1216 rectangle highlighting the altered outer ear phenotype. Scale bars represent 1 cm.

1217 **f**, Statistical analysis of the inferior pinna area, marked by the red dotted box in e, is shown. Data
1218 are presented as mean ± S.E.M. (n = 15).

1219 **g**, Top view comparison of wild type and homozygous mEC1 knock-in mouse models, with sections
1220 within the red rectangle enlarged in the bottom panel. Notably, the helix rim is wrinkled in the
1221 transgenic mouse model, as indicated by the red angle. Scale bars measure 1 cm.

1222 **h**, Statistical analysis is conducted on the angle representing the extent of helix folding. Data are
1223 shown as mean ± SEM (n = 15).

1224 **i, j**, Whole-mount *in situ* hybridization (WISH) showing *Hmx1* expression in WT and *mEC1^{dup/dup}*
1225 embryos at E10.5 (i) and E14.5 (j). The white arrow indicates expanded *Hmx1* expression in the
1226 middle PA2 region (i) and in the upper part of the outer ear (j). Scale bars are 50 µm (i) and 1000
1227 µm (j), respectively.

1228 **k**, Loss of *Hmx1* expression through three different strategies results in a similar low-set and
1229 protruding ear phenotype. These strategies include *Hmx1^{fl/fl}* (homozygous flox allele),
1230 *Wnt1::Cre;Hmx1^{fl/fl}* (conditional deletion of *Hmx1* in neural crest cells), and *mEC1^{del/del}*
1231 (homozygous deletion of mEC1). The 'dumbo' mutation, representing a missense mutation in exon
1232 1 of *Hmx1*, results in a truncated protein. Scale bars measure 1000 µm.

1233 **l**, Micro-CT analysis of ear-related structure in different mouse models at eight weeks, nine months
1234 and one year. The gold arrow points to the mastoid process.

1235

1236 **Fig. 6 | *Hmx1* misexpression in mouse leads to widespread abnormal development in pinna
1237 structures including cartilage, fibroblasts, muscle, and epidermis**

1238 **a**, RNA-seq analysis compares the whole pinna structure between wild-type and E14.5 *mEC1^{dup/dup}*
1239 mice. Each dot represents a single gene. Differentially expressed genes (DEGs) are defined as FDR
1240 ≤ 0.05, log2 CPM ≥ 1, and |log2 FC| ≥ 0. Up- and down-regulated genes are shown as gold and blue
1241 dots, respectively. DEGs with |log2 FC| ≥ 1 are highlighted and labeled, previous reported cartilage
1242 development-related genes including *Comp*⁸⁰ and *Arhgap36*⁸¹ were marked as red.

1243 **b**, Gene Ontology (GO) enrichment analysis of 284 downregulated genes is performed. The top 30
1244 GO terms are displayed and grouped into four clusters.

1245 **c**, Masson's trichrome staining at E14.5 (upper and lower pinna parts) is shown for WT and
1246 *mEC1^{dup/dup}*. Scale bars measure 200 μ m.
1247 **d**, UMAP dimensional reduction visualizes *Hmx1*⁺ expressed cells combined across E10.5, E12.5,
1248 and E14.5.
1249 **e**, A dot plot displays two marker genes for each cluster identified within the fibroblasts. The cell
1250 clusters of 1-7 is same as in d.
1251 **f**, Developmental trajectory analysis from E10.5 CNCC mesenchymal cells (cluster 6) to the
1252 fibroblasts defined in (e) is illustrated. The cell clusters of 1-7 is same as in d.
1253 **g**, The expression of cartilage, fibroblast, muscle, and epidermis development-related
1254 downregulated DEGs across nine cell clusters (including 7 fibroblast, chondrocyte, and myogenic
1255 cell clusters) is shown. The heatmap on the left panel depicts the fold change of each gene.
1256 **h, i**, *In situ* hybridization staining for *Hmx1* and *Dmkn* expression in wild-type and *mEC1^{dup/dup}*
1257 embryos at upper (**h**) and lower (**i**) regions of the pinna.
1258

1259 **Fig. 7 | Model**

1260 **a**, Stage-specific enhancer activities in hCNCCs in the BCE locus. EC2 may be initiated at the early
1261 hCNCCs stage, driving weak expression of *HMX1*; EC1 drives most *HMX1* transcriptional output
1262 at the PA-like hCNCCs stage, and EC3 may serve as a structural element.
1263 **b**, Coordinated and synergistic PI-HEC patterning in PA2 and pinna zones. EC2.1, EC2, and EC3,
1264 represented by varying color intensities, are weak enhancers.
1265 **c**, A motif pattern consisting of TALE-type HDs (HOXA2/MEIS1/PBX1), HMG box (TCF7L1/2),
1266 and Coordinator (TWIST1/TCF4) endows the dominant EC1 with specificity and activity.
1267 **d**, A comprehensive disease model for BCE. Based on scRNA-seq and *mEC1^{dup/dup}* mouse model,
1268 we demonstrated that *Hmx1* is mainly responsible for CNCCs-derived fibroblasts development in
1269 pinna structure, and duplication of EC1 causes aberrant expression of *Hmx1* in fibroblasts and
1270 ectopic expression in the other zones of the pinna, disrupting the gene network in cartilage, muscle,
1271 epidermis, and leading to outer ear malformation.
1272
1273

1274 **Extended Data Fig. 1 | Identification and fine mapping of the BCE Locus in three BCE**
1275 **pedigrees.**

1276 **a**, Linkage analysis using whole-genome chip-based data in three BCE families revealed a
1277 pronounced signal on chromosome 4, marked by a LOD score of 7.8. This highlights a shared
1278 chromosomal region associated with the BCE phenotype.
1279 **b**, A detailed representation of the chromosome 4 linkage signal, including individual LOD scores
1280 for each family. This demonstrates the distinct yet overlapping linkage signals among these families.
1281 **c**, Fine mapping of the linkage signals identified copy number duplications through target capture
1282 sequencing. For each family, one healthy individual was randomly selected as a control. This
1283 panel compares the sequencing coverage depth ratio between the remaining family members and
1284 this healthy control. Red lines illustrate the read depth ratio in the linked chromosomal region for
1285 patients compared to the control, whereas blue lines depict the ratio between healthy family
1286 members and the control.
1287

1288 **Extended Data Fig. 2 | Single-Cell RNA sequencing and epigenetic landscaping of the BCE**
1289 **locus in human and mouse craniofacial development.**

1290 **a**, UMAP clustering and *HMX1* expression profiling in early human embryonic craniofacial regions.
1291 scRNA-seq analysis showcases the UMAP clustering of cell types from the human early
1292 organogenesis atlas, with cell type annotations as per Xu, Y. *et al.* (2023)²³. The central feature plot
1293 visualizes the expression levels of the *HMX1* gene across different cell clusters, while the right panel
1294 provides a detailed view of *HMX1* expression within craniofacial mesenchyme cells specifically in
1295 the pharyngeal arch (PA) structures.

1296 **b**, Conservation of epigenetic regulatory elements in mouse E8.5 NCC progenitors and E10.5 Md,
1297 PA2 NCCs. This panel illustrates the epigenetic landscape at the BCE locus in mouse neural crest
1298 cell progenitors at E8.5 and E10.5 using public available datasets¹⁷. Highlighted in yellow are the
1299 regions orthologous to human enhancers and the *Hmx1* promoter.

1300 **c**, Dynamics of the BCE locus epigenetic landscape from mouse pharyngeal arch 2 (PA2) to pinna
1301 development. Here, the evolution of the epigenetic context is traced from E10.5 PA2 to E14.5 pinna
1302 tissues using public available datasets²⁶. Blue and red arcs indicate chromatin interactions from two
1303 Promoter Capture Hi-C (PC-HiC) dataset replicates. ATAC-seq and CTCF tracks are also shown.

1304
1305 **Extended Data Fig. 3 | *In vitro* differentiation system from H9 cells to PA-like hCNCCs state**

1306 **a**, Representative images depicting the progression from H9 cells to the late hCNCCs state.

1307 **b**, Immunofluorescence analysis using markers p75, NR2F1, AP2, and SOX9 to verify cell identity
1308 during the differentiation process.

1309 **c**, Quantitative real-time PCR (qPCR) is used to further evaluate the efficiency of hCNCCs
1310 differentiation. Results are presented as mean ± SEM (n = 3).

1311 **d**, Representative images illustrating the transition from late hCNCCs to PA-like hCNCCs state.

1312 **e**, Gene expression analysis of pharyngeal arch 2-specific TFs, including *HOXA2*, *MEIS1*, *PBX1*,
1313 *TBX15*, and *DLX6*. Data are expressed as mean ± SEM (n = 4).

1314
1315 **Extended Data Fig. 4 | Spatiotemporal regulation of *Hmx1* expression by multipartite
1316 enhancers**

1317 **a**, A CRISPR/Cas9 strategy is employed to delete the hEC1+hEC2 region (~9 kb). Six gRNA
1318 sequences are designed along with corresponding primer pairs to validate knockout efficiency, with
1319 gel analysis images provided.

1320 **b**, Representative images illustrate early hCNCCs migration in both wild-type (WT) and knockout
1321 (KO) cell lines. In the right panel, FACS analysis of CD271 (p75) in early hCNCCs is shown for
1322 both WT and KO cell lines.

1323 **c**, Gene expression analysis of *SOX9* and *TWIST1*, two important TFs in hCNCCs, compares WT
1324 and KO. Data are presented as mean ± SEM (n = 4).

1325 **d-i**, LacZ assays are conducted to track pinna development for various enhancers: hEC1 (d), hEC2.1
1326 (e), hEC2 (f), hEC1+hEC2 (g), hEC3 (h), and hEC1+hEC2+hEC3 (i). Results showing all positive
1327 LacZ staining embryos for each enhancer are included.

1328 **j**, The construction of the *Hmx1*-P2A-EGFP transgenic reporter line is described, with Sanger
1329 sequencing results of this mouse model presented.

1331 **Extended Data Fig. 5 | HD, HMG box and Coordinator TFs coordinately regulate hEC1**
1332 **specificity and activity.**

1333 **a**, Display all positive LacZ staining embryos for Δ D1, Δ D2, Δ D3, Δ D4, and Δ D5. Arrows point to
1334 faint staining signals.

1335 **b**, A schematic process of DNA pull-down using PA2 tissue from E11.5 mouse embryos and
1336 biotinylated hEC1 is presented.

1337 **c**, Gene enrichment analysis of proteins identified in the DNA pull-down assay is conducted.. For
1338 fifteen DNA-binding proteins, InterPro enrichment is further performed on the DAVID website to
1339 detect TF classification.

1340 **d**, A heatmap is presented, showing IgG, H3K27ac, and TCF7L2 binding profiles across ± 2 kb from
1341 TCF7L2 peak summits (4560). Results from two independent biological replicates are shown.

1342 **e**, *De novo* TCF7L2 motif analysis is performed using the MEME toolkit. The top-ranked motif is
1343 similar to TF7L2_HUMAN.H11MO.O.A; the eighth-ranked motif is similar to
1344 TWIST1_HUMAN.H11MO.O.A.

1345

1346 **Extended Data Fig. 6 | Pinna malformation is driven by either the expansion or the loss of**
1347 **spatial *Hmx1* expression**

1348 **a**, A schematic diagram of the transgenic mEC1^{dup/dup} mouse model is presented. A primer pair, P1
1349 and P2, flanking the mEC1 element, is designed for genotyping: the wildtype allele measures 2374
1350 bp and the transgenic allele 3487 bp. The right panel displays gel electrophoresis results for wildtype
1351 (WT), heterozygote (Het), and homozygote (Homo) in the white rectangle.

1352 **b**, This figure Depicts all positive LacZ staining in mouse embryos for mEC1 at E14.5. The upper
1353 panel shows the whole embryo, while the bottom panel presents zoomed-in images of pinna staining.
1354 Black arrows and stars indicate distinct staining patterns compared to hEC1 LacZ results,
1355 particularly in the frontonasal prominence and fore- and hind-limbs.

1356 **c**, Ear and eye malformations are compared between wildtype and *mEC1*^{dup/dup} mice. Ear
1357 malformation in *mEC1*^{dup/dup} is clearly visible, as indicated by the white arrow. Eye malformation,
1358 likely representing cataract, is marked with a red rectangle in older mice.

1359 **d**, A schematic diagram of the transgenic *wnt1::Cre;Hmx1^{fl/fl}* mouse model is shown. Primers F1,
1360 R1 are used to identify WT and *Hmx1^{fl/fl}*; and F2, R1 for genotyping *Wnt1::Cre;Hmx1^{fl/fl}*.

1361

1362 **Extended Data Fig. 7 | ScRNA-seq reveals the critical role of *Hmx1* on the ear fibroblast**
1363 **development.**




1364 **a**, This figure depicts Lineage tracing of *Hmx1*⁺ cells from E10.5 to E14.5 using the Hmx1-P2A-
1365 EGFP mouse reporter line. Fluorescence images for each timepoint are shown, with tissues micro-
1366 dissected for dissociation marked by white rectangles. *GFP*⁺ cells are collected using FACS.



1367 **b**, UMAP dimensional reduction visualization of *Hmx1*⁺ expressing cells for each timepoint is
1368 presented.

1369 **c**, Marker genes used for cell cluster annotation are identified.

1370

1371

a**b****c****Figure 1**

a**b****Figure 2**





Figure 3












Figure 5

a**b****c****d**

Clusters

- 1 Skeletal muscle-related fibroblast
- 2 *Enpp2* Fibro-adipogenic progenitors
- 3 *Osr1* Fibro-adipogenic progenitors
- 4 Upper dermal fibroblast progenitors
- 5 Lower dermal fibroblast progenitors
- 6 Mitotic CNCC-derived mesenchymal cells
- 7 Perimysial cells
- 8 Neurons
- 9 Neuroglia cell
- 10 Myogenic cell
- 11 Motor neurons
- 12 Myocytes
- 13 Chondrocytes
- 14 Unknown

g**h****i****Figure 6**















Figure 7









Extended Data Figure 1




a**b****c**

Extended Data Figure 2





a**b****c****d****Extended Data Figure 3**

a**b****c****d****j****Hmx1-P2A-EGFP mouse line**




Extended Data Figure 4



Extended Data Figure 5

a**b****c****d**

Extended Data Figure 6

a**c****b**

- 1 *Ogn* *Mest* Fibro
- 2 *Enpp2* Fibro-adipogenic progenitors
- 3 *Osr1* Fibro-adipogenic progenitors
- 4 Upper dermal fibroblast progenitors
- 5 Lower dermal fibroblast progenitors
- 6 Mitotic CNCC-derived mesenchymal cells
- 7 Perimysial cells
- 8 Neurons
- 9 Neuroglia cell
- 10 Myogenic cell
- 11 Motor neurons
- 12 Myocytes
- 13 Chondrocytes
- 14 Unknown

Extended Data Figure 7